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1. Introduction 
The last four decades witnessed a brilliant career of proteoglycans (PGs). Once regarded as 
mere space-fillers or passive structural components of matrices and charge-selective 
barriers, these fascinating molecules have been increasingly acknowledged as key players in 
cell-cell and cell-matrix communication, and have become recognized as modulators of 
most, if not all, aspects of cell behavior including survival, proliferation, and migration. 
Simultaneously, the range of disease processes with known involvement of PGs has steadily 
expanded, now covering areas as diverse as host-pathogen interactions, regulation of 
pathologic fibrogenesis, and tumor progression. Characteristic alterations of PGs in various 
human malignant tumors, including HCC, were first described more than 20 years ago (for 
an early review, see Tímár & Kovalszky, 1995). 
PGs, glycanated proteins with extensive posttranslational modifications, consist of a protein 
core and one or more long, linear, sulfated polysaccharide chains, called 
glycosaminoglycans (GAGs). GAGs are ligated to the protein core at specific serine, 
threonine, or asparagine residues, although the exact signal sequences that designate the 
position of attachment are mostly unknown. The multifunctionality of PGs arises from their 
inherently complex structure: some functions are assigned to the core protein, while others 
are fulfilled by the GAG chains. 
The synthesis of each GAG chain (recently reviewed by Ly et al., 2010) is introduced by the 
attachment of a short linkage region to Ser in the case of heparan sulfate (HS)/heparin and 
chondroitin sulfate/dermatan sulfate (CS/DS), and either Asn or Ser/Thr in the case of 
keratan sulfate (KS) type I and type II, respectively. During the elongation phase of GAG 
synthesis, acetylated hexosamine and hexuronic acid or galactose residues are added in an 
alternating fashion to the growing polysaccharide chain. GAGs are classified by their 
disaccharide composition: the dimeric building block is N-acetyl-glucosamine / glucoronic 
acid in HS and heparin; N-acetyl-galactosamine / glucoronic acid in CS and DS; and N-
acetlyl-glucosamine / galactose in KS. Completed GAG chains then undergo various 
chemical modifications including N-deacetylation, N- and O-sulfation, and epimerization of 
the hexuronic acid. Heparin, for example, differs from HS in the extent of sulfation (heparin 
is sulfated uniformly and nearly exhaustively, whereas HS is sulfated only partially and in a 
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patterned manner); and DS differs from CS in the degree of uronic acid epimerization (0% in 
CS vs. 1-100% in DS.) The extent and pattern of modifications not only vary between 
different GAGs and PGs, but also depend on the type and actual state of a cell, which 
contributes a great deal to the biological diversity of PGs. If this were still not enough of 
versatility, PGs may undergo further editing once they are in place: in the matrix or on the 
cell surface, they may be subject to the action of endoglycosidases that cleave the GAG 
chain, proteases that cut the protein core, and endosulfatases capable of removing sulfate 
groups from internal sugar residues. 
Historically, PGs were sorted by the type of their GAG chain into one of the categories 
HSPG, CS/DSPG, or KSPG. Later, however, the discovery that several PGs carry more 
than one type of GAG (i.e., syndecans and betaglycan carry both HS and CS; aggrecan 
carries both CS and KS II) prompted a new classification based on structure and tissue 
localization. In this revised system, each PG belongs to one of three major families: 1) 
small leucine-rich proteoglycans or SLRPs; 2) modular PGs, further divided into a) 
hyalectans or hyaluronan-binding PGs and b) non-hyaluronan-binding PGs of the 
basement membrane; and 3) cell surface PGs. Nevertheless, both the old and new 
classifications fall short of being perfect; neither is free of overlaps, and neither can 
properly accommodate, for example, serglycin or endocan. In this review, we shall follow 
a sort of “hybrid” classification that fits best for our purposes. 
A complete listing of all currently known PGs seems unnecessary here (for a comprehensive 
review, the Reader is referred to Esko et al., 2009); this paper is restricted in scope to PGs 
present in the healthy or diseased liver, and will concentrate on those involved in, or 
affected by, chronic liver disease and hepatocarcinogenesis. Also, with a focus on human 
disease, PGs reported to be present in the liver of experimental animals but not of humans 
will be omitted. 
2. Proteoglycans in the liver 
The healthy liver is a dominantly parenchymatous organ with relatively scarce stroma. 
Consequently, cell surface PGs expressed by hepatocytes are considerably more abundant 
than matrix PGs, either small or modular. Chronic liver diseases, on the other hand, are 
hallmarked by the accumulation of connective tissue, and PGs, along with other matrix 
constituents, become massively deposited as fibrosis progresses. Hepatocarcinogenesis is 
accompanied by further alterations in liver PG profile. These disease-associated changes are 
reflected in gene expression levels (i.e., of PG core proteins and GAG synthesis / modification 
enzymes), in the abundance and/or localization of PGs, and in the quantity and structure of 
GAGs in the tissue. Specific PGs present in the healthy or diseased liver, their pathology-
related changes, as well as known or proposed functions in liver physiology or disease, are 
listed concisely in Table 1 (on pages 3-4), and discussed in detail in the following sections. 
2.1 SLRPs 
The family of SLRPs, extracellular PGs characterized by relatively small (approx. 30-70 kDa) 
core proteins with leucine-rich repeats and conserved cysteine-containing motifs, currently 
counts 18 members divided into 5 classes (Schaefer & Iozzo, 2008; Schaefer & Schaefer,  
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2010). While most SLRPs carry CS/DS or KS chains, some of them are non-classical PGs 
lacking GAG chains altogether, and can thus be considered as “honorary” members of the 
PG superfamily that have been grouped together with SLRPs on the basis of structural 
and functional homology. So far, only three SLRPs were found in the liver: decorin, the 
prototypical member of the family; biglycan; and asporin, a non-canonical, GAG-less 
relative of the former two. Whereas reports leave ambiguity regarding the mere presence 
of asporin (its mRNA was abundant in the human liver but undetectable in mice) 
(Lorenzo et al., 2001; Henry et al., 2001), decorin has been widely implicated in liver 
fibrogenesis, and may also play a role in the regulation of hepatocellular carcinoma (HCC) 
growth. Knowledge on biglycan in the liver is much more limited; nevertheless, 
mentioning will be made of it. 
Decorin, the archetypal SLRP, is glycanated with a single CS/DS chain, and was originally 
described as a regulator of collagen fibrillogenesis. Later, an increasingly complex picture 
has emerged: decorin was found to modulate the signaling of transforming growth factor- 
┚1 (TGF-┚1), a key stimulator of fibrogenesis, and it also became evident that decorin 
establishes contacts with multiple receptor tyrosine kinases (RTKs) such as epidermal 
growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGF-IR), and Met 
(Iozzo & Schaefer, 2010). Decorin has a broad tissue distribution, being most abundant in the 
skin, connective tissues, muscles, and the kidney (Kalamajski & Oldberg, 2010). 
In the healthy liver, strong decorin immunoreaction is solely seen in the Glisson’s capsule, 
with some positive labeling around central veins, and only delicate, spot-like extracellular 
staining in the periportal connective tissue and, occasionally, in sinusoidal walls. In the 
course of chronic liver injury, however, decorin accumulates in the areas of periportal and 
bridging fibrosis, and becomes increasingly deposited in sinusoidal walls as capillarization 
ensues. Co-localization studies suggest association of decorin with collagen fibers, and its 
interaction with TGF-┚1 (Dudás et al., 2001). 
Decorin can directly bind and sequester TGF-┚1, or indirectly influence its effect via 
association with the LRP-1 receptor (Cabello-Verrugio & Brandan, 2007). While the net 
outcome of these interactions depends on the cell type, decorin seemed to inhibit TGF-┚1-
dependent fibroblast proliferation and matrix production in the context of experimental 
renal fibrogenesis (Isaka et al., 1996). Importantly, decorin exerted a similar inhibitory effect 
on a human hepatic stellate cell (HSC) line in vitro (Shi et al., 2006). Since activated hepatic 
stellate cells are the major culprits in liver fibrosis, decorin might limit worsening of the 
condition, and the use of decorin as a TGF-┚1 blocking agent for the treatment of chronic 
liver disease has been repeatedly proposed (Breitkopf et al., 2005). A recent report provides 
indirect support to this approach, demonstrating increased susceptibility to thioacetamide-
induced fibrogenesis, and impaired recovery from established fibrosis in decorin-null mice 
(Baghy et al., 2011). The absence of decorin, with consequently higher activity of TGF-┚1, not 
only increased fibrogenesis but also impeded resolution of fibrosis by interfering with 
matrix metalloprotease action. However, the transferability of these results to human liver 
fibrosis is unclear. At least, massive accumulation of decorin in the course of chronic liver 
disease indicates that, even if interpreted as a defense mechanism, overexpression of decorin 
is largely inefficient in preventing fibrosis. Being itself upregulated by TGF-┚1 in HSCs 
(Baghy et al., 2011), the deposition of decorin in the connective tissue is more likely a by-
product of fibrogenesis rather than a protective reaction against it. 
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While little is known about the involvement of decorin in hepatic carcinogenesis, available 
studies unequivocally assign an antitumor role to decorin in HCC. Decorin has been 
reported to be downregulated in HCC tissue relative to the normal liver (Miyasaka et al., 
2001; Chung et al., 2002), and it became re-expressed in the HCC cell line SMMC-7721 upon 
knockdown of DNA methyltransferase 1 (Fan et al., 2007), indicating active repression by 
the tumor cells. Moreover, decorin was found to inhibit proliferation of HuH7 cells in a 
concentration-dependent manner (Shangguan et al., 2009), and killed xenografted HCC cells 
via adenoviral gene transfer (Tralhão et al., 2003). These findings are in good agreement 
with the general view that decorin, via its suppressive interactions with TGF-┚1 and RTKs, 
and upregulation of p21, attenuates cell proliferation, possibly curbs angiogenesis, and thus 
inhibits both primary growth and metastatic spread of tumors (Goldoni & Iozzo, 2008). 
However, an expected inverse correlation between decorin expression and aggressive 
behavior of HCC still waits to be demonstrated. 
Biglycan, another class I member SLRP, was found to be produced by activated HSCs during 
rat and human fibrogenesis (Gressner et al., 1994), and it is strongly deposited in fibrotic 
areas along with decorin (Högemann et al., 1997). Biglycan, like decorin, is also known to 
interact with members of the TGF┚/BMP family (Schaefer & Iozzo, 2008); however, up to 
now, no mechanistic details of its contribution to liver disease have been revealed. 
2.2 Modular and cell surface HSPGs 
Just like SLRPs span multiple classes of the old PG nomenclature, HSPGs cross the 
borders of the new classification, with some members belonging to the non-hyaluronan-
binding modular group and others to the cell surface group. However, the many common 
features they share owing to their HS chains speak for the conservation of the traditional 
HSPG category.  
HSPGs are by far the most thoroughly studied representatives of the PG superfamily. This 
distinctive attention is all but unmerited: due to the incredibly broad spectrum of their 
functions, HSPGs permeate all fields of mammalian physiology (for a comprehensive 
review, see Bishop et al., 2007). The paradigm that GAGs can specifically bind extracellular 
mediators such as growth factors and cytokines, regulate their availability and activity, and 
assist their binding to primary receptors, has been derived from the study of HS, and 
knowledge on other GAGs in this respect is still lagging behind. The interaction of HS with 
fibroblast growth factors (FGFs) and their receptors has been characterized in greatest detail 
(Pellegrini, 2001), but a host of other heparin-/HS-binding growth factors and mediators 
have been identified (Dreyfuss et al., 2009). HS synthesis, structure, function, and 
modifications have been extensively reviewed elsewhere (for references, see Esko et al., 
2009); hence, only a brief outline is provided here. 
Following synthesis of the N-acetyl-glucosamine/glucuronic acid (GlcNAc/GlcUA) 
copolymer, the prospective heparin/HS molecule undergoes extensive modifications. 
GlcUA residues may be epimerized into iduronic acid (IdoUA); N-acetyl groups may be 
removed and replaced by N-sulfates; and further sulfates may be transferred to the 6-O and 
3-O positions on GlcN, as well as to the 2-O position of IdoUA. These modifications are 
carried out by epimerase, N-deacetylase-sulfotransferases (NDSTs), and position-specific O-
sulfotransferases (OSTs), respectively; some of these enzymes have several isoforms. 
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Whereas epimerized, N-, 2-O- and 6-O-sulfated disaccharides are predominant and 
uniformly distributed in heparin, HS is characterized by the alternation of unmodified (N-
acetylated) and modified (N-sulfated) regions, the latter being flanked by partially modified 
transition zones. The rarest modification in both heparin and HS is 3-O-sulfation which, 
however, is indispensable for important biological functions such as antithrombin binding 
(Chen & Liu, 2005). Unlike heparin, native HS has little anticoagulant activity; on the other 
hand, it possesses a delicate fine structure that is pivotal in determining its specificity and 
affinity towards potential binding partners. Consequently, even subtle alterations in the 
sulfation pattern of HS may substantially affect its biological properties. 
HS may be further shaped post-synthetically by the action of heparanase, a secreted 
endoglucuronidase capable of cleaving the polysaccharide in a limited fashion, and the 
SULFs, endosulfatases removing 6-O-sulfate groups from specific disaccharide motifs. Since 
these enzymes also modulate the growth factor binding properties of HS, their activities 
have broad implications for tumor growth, angiogenesis, and metastasis. 
Of course, HSPGs possess a protein core, too, which may participate in a number of 
interactions. The complex modular structure of matrix HSPGs warrants their involvement in 
intricate protein networks within the matrix as well as between matrix and cells; thus, they 
often occupy a bridging position between the matrix and cell surface. Transmembrane 
HSPGs may similarly establish contacts with the matrix, but may also associate with other 
cell surface receptors or recruit cytoskeletal and signaling proteins via their cytoplasmic 
domain (Mythreye & Blobe, 2009). 
2.2.1 Modular HSPGs of the basement membrane: Perlecan, agrin, and collagen type 
XVIII 
Perlecan. This large HSPG, consisting of numerous modules grouped into five major 
domains, is secreted into the pericellular space. Perlecan, ubiquitously found in basement 
membranes (BMs) and other extracellular matrices, is strategically positioned to mediate 
signaling events related to cell migration, proliferation, and differentiation. Most of its 
functions are assigned to the HS chains capable of binding growth factors, but the modular 
protein core also participates in numerous cell-matrix and matrix-matrix interactions 
(Whitelock et al., 2008). 
Perlecan was detected in the healthy liver in all BMs, including those of bile ducts and blood 
vessels; even in the poorly organized BM of sinusoids. Endothelial cells, portal 
mesenchymal cells, and arterial walls were also immunopositive for perlecan (Roskams et 
al., 1995). Accumulation of perlecan in chronic liver disease is mainly attributable to 
ductular reaction and sinusoidal capillarization, although perlecan appears not only in BMs 
but diffusely in connective tissue septa (Roskams et al., 1996; Kovalszky et al. 1998). In HCC, 
robust perlecan immunostaining labels the vasculature of the tumor (Roskams et al., 1998). 
The role of perlecan in the pathomechanism of chronic liver diseases and HCC has not been 
investigated. Data on the role of perlecan in fibrogenesis are missing altogether, and 
inferences regarding HCC can be drawn from studies on other cancer types only. Perlecan 
plays a central role in both developmental and pathologic angiogenesis (Iozzo & Sanderson, 
2011). Intriguingly, perlecan can either stimulate or inhibit angiogenesis by two entirely 
distinct mechanisms. Its stimulatory role is primarily explained by the high capacity of its 
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HS chains to bind vascular endothelial growth factor (VEGF) and FGF-2, two major 
proangiogenic factors. Deposited around tumor cells and in capillary basement membranes, 
perlecan is ideally situated to support neovessel growth. Perlecan is supposed to act in 
concert with heparanase that liberates bound growth factors from its HS chains, or alone by 
cross-linking VEGF receptor with integrins on the surface of endothelial cells. The 
antiangiogenic effect, on the other hand, is exerted by a C-terminal proteolytic fragment of 
perlecan, termed endorepellin. Binding of endorepellin to ┙2┚1-integrin, a master matrix 
receptor of endothelial cells, triggers disruption of the cytoskeleton and blocks endothelial 
migration and survival. This dual nature of perlecan notwithstanding, both experimental 
and clinical data indicate that the proangiogenic role dominates in human malignancies, and 
perlecan promotes progression of various tumor types including carcinomas of the breast, 
prostate, and colon, as well as metastatic melanoma (Bix & Iozzo, 2008). Although the role of 
perlecan in HCC progression has not yet been specifically addressed, it is tempting to 
speculate that it may favor neovessel growth in this hypervascular tumor type. 
Agrin. Another large HSPG with complex domain structure, agrin shares some homology 
with perlecan, but possesses many unique features and is probably less ubiquitous in the 
body. One peculiarity of agrin is the existence of both secreted and membrane-bound 
isoforms. Agrin was first described as organizer of the postsynaptic receptor apparatus in 
neuromuscular junctions, and was subsequently shown to play a similar role in the central 
nervous system. It was later found in the renal glomerular basement membrane, on the 
surface of immune cells, and in the blood-brain barrier (Bezakova & Ruegg, 2003).  
In the healthy liver, agrin is so scarce that it was understandably missed on the first survey 
(Gesemann et al., 1998). No sooner than its accumulation in cirrhosis and HCC raised 
attention could the purposeful quest find some agrin in the walls of portal blood vessels and 
in the BM of bile ducts (Tátrai et al., 2006). Similar to perlecan, increased deposition of agrin 
during chronic liver injury is associated with ductular reaction and neovessel formation in 
the connective tissue septa; however, in contrast with perlecan, no diffuse agrin 
immunostaining is seen in fibrotic areas, and agrin is virtually absent from all sinusoids, 
either healthy or capillarized. In HCC, agrin is deposited in a pattern similar to that of 
perlecan, i.e. in the wall of tumoral blood vessels. Since agrin, unlike perlecan, is missing 
from normal and cirrhotic sinusoids, the appearance of agrin in microvascular walls is a 
useful immunohistochemical marker of malignant hepatocellular transformation (Tátrai et 
al., 2009). To date, no mechanistic or clinical data are available on the role of agrin in HCC, 
or in tumor biology as a whole. With only a priori knowledge at hand, a proangiogenic role 
can be hypothesized, based on agrin’s structural and functional similarities with perlecan, 
including the ability of its HS chains to bind growth factors and the possible interactions of 
its core protein with integrin receptors (Burgess et al., 2002). 
Collagen type XVIII, a ubiquitous BM-HSPG (reviewed by Iozzo et al., 2009; Seppinen & 
Pihlajaniemi, 2011) combines features of collagens and modular PGs. Three variant forms of 
collagen type XVIII result from alternative transcription initiation sites and splicing. The 
shortest one is found in most vascular, muscle fiber and epithelial BMs as well as in various 
ocular structures, whereas the two long variants are expressed predominantly in the liver. 
Despite its widespread presence in vascular BMs, collagen XVIII does not seem to be 
essential for blood vessel development; rather, its mutations lead to malformations of the 
eye and the central nervous system. Main functions of collagen XVIII are linked to its role in 
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maintaining the structural integrity of BMs, especially those in the eye, as well as to the anti-
angiogenic effect of its C-terminal proteolytic fragment termed endostatin. Endostatin 
(O’Reilly et al., 1997), a potent endogenous inhibitor of angiogenesis, can be liberated from 
full-length collagen XVIII by matrix proteases, and interferes with virtually every step of the 
angiogenic process. It curbs proliferation and migration of endothelial cells and promotes 
their apoptosis; impedes the recruitment of pericytes; and reduces mobilization of 
endothelial progenitor cells into the circulation. The mechanism of action of endostatin is 
complex, involving multiple pathways such as ┙5┚1-integrin-, VEGFR-, and Wnt/┚-catenin 
signaling (Seppinen & Pihlajaniemi, 2011). External administration of endostatin, either as 
recombinant protein or in the form of gene therapy, has been shown to suppress growth of 
numerous animal and xenografted human tumor types including HCC (Folkman, 2006). 
As mentioned above, collagen XVIII is abundant in the healthy liver, where it is deposited 
both perisinusoidally and in BM zones of bile ducts, blood vessels, and peripheral nerves 
(Musso et al., 1998). Unlike most other extracellular matrix (ECM) proteins which are 
produced primarily by HSCs, collagen XVIII in the normal liver mostly originates from 
hepatocytes. Liver parenchymal cells produce both long variants under liver-specific 
transcriptional control; interestingly, variant #2 is secreted into the plasma rather than 
retained in the sinusoidal BM. Non-parenchymal cells such as bile duct epithelial, 
endothelial, and vascular smooth muscle cells express the short, ubiquitous variant (Musso 
et al., 2001a). Activated HSCs step on the stage in active fibrosis, and short collagen XVIII 
becomes a major component of remodeled BM in capillarized sinusoids; then, in quiescent 
cirrhosis, hepatocytes once again take over the primacy in collagen XVIII synthesis. 
It seems proven that HCC cells initially maintain or even increase their expression of long 
collagen XVIII, and stromal cells continue to produce short collagen XVIII in HCC (Musso et 
al., 2001a, 2001b). Controversy exists, on the other hand, as to whether collagen XVIII levels in 
tumor hepatocytes increase or decrease with HCC progression. While some authors 
demonstrate that high tumoral expression of collagen XVIII correlates with increased VEGF 
activity and poor prognosis (Hu et al., 2005), others argue that, as it can be expected of an 
angiogenesis suppressor, collagen XVIII becomes downregulated by HCC cells in parallel with 
increasing tumor size, microvessel density, and clinical aggressiveness (Musso et al., 2001b). 
Since long collagen XVIII variants are regulated by liver-specific transcription factors, it has 
been suggested that their downregulation may reflect the loss of hepatocytic phenotype. It has 
also been proposed that decreased tumoral expression of the longest (#3) variant may favor 
progression by allowing higher activation of the Wnt/┚-catenin pathway (Quélard et al., 2008). 
Variant #3 possesses a domain homologous to the Wnt-receptor frizzled which, when cleaved 
off proteolytically, localizes to the cell surface and blocks Wnt/┚-catenin activation by 
sequestering Wnt3a. Thus, downregulation of variant #3 may relieve this block and allow 
enhanced tumor growth. Moreover, in further support of decreased tumoral expression of 
collagen XVIII, higher levels of endostatin were found in adjacent liver tissue relative to HCC 
in a tissue array-based immunohistochemical study (Yu et al., 2010). 
2.2.2 Cell surface HSPGs: Syndecans and glypicans 
Syndecans. All four members of this transmembrane cell surface HSPG family (reviewed by 
Xian et al., 2010) share highly conserved membrane-spanning domains and cytoplasmic 
regions, while their extracellular domains are divergent. Syndecans play prominent roles in 
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cell-cell and cell-ECM interactions including cell adhesion, as well as in matrix organization 
and assembly. Via their intracellular domain they can communicate with actin-associated 
and signaling molecules; some of their intracellular partners are PDZ domain-containing 
proteins. Unlike giant multimodular HSPGs, the core protein of syndecans is rather small, 
ranging between 20-40 kDa. Besides HS chains, syndecan-1 and -3 may also bear CS/DS 
GAGs. The extracellular domain of syndecans may be cleaved off proteolytically and 
solubilized in a process referred to as ectodomain shedding, which is effected by matrix 
metalloproteinases (Couchman, 2010). 
Of the four family members, syndecan-1, a ubiquitous epithelial membrane HSPG, is the 
most abundant in the healthy liver. Syndecan-1 is robustly expressed on hepatocytes, 
resulting in a primarily sinusoidal and, to a lesser extent, lateral membrane-associated 
immunostaining pattern. Syndecan-1 is also present on biliary epithelial cells, with 
basolateral accentuation, and on sinusoidal but not on portal vessel endothelial cells 
(Roskams et al., 1995).  
Endocytic clearance of triglyceride-rich lipoprotein remnants, a major metabolic task of 
hepatocytes, is mediated by HS as a receptor, and syndecan-1 has been identified as the 
primary HSPG involved in this process (Stanford et al., 2009; Williams & Chen, 2010). Cell 
surface HS is also a main clue for pathogens in the recognition of their host cells and in 
endocytic entry (Y. Chen et al., 2008). Plasmodium sporozoites dock on hepatocytes using HS 
receptors (Pinzon-Ortiz et al., 2001); it has been suggested that blood-borne sporozoites are 
literally “filtered out” by liver-specific, highly sulfated HS structures (Pradel et al., 2002; 
Coppi et al., 2007). Furthermore, HSPGs act as receptors or co-receptors for obligate and 
facultative hepatotropic viruses including dengue, hepatitis B, C, and E viruses (Hilgard & 
Stockert, 2000; Barth et al., 2003; Schulze et al., 2007; Kalia et al., 2009). The previously 
established role of HS in adenoviral infection of the liver is currently a matter of debate (Di 
Paolo et al., 2007; Bradshaw et al., 2010; Corjon et al., 2011). Being the major liver cell 
membrane HSPG, syndecan-1 may plausibly turn out to be the key mediator in most 
hepatocyte-pathogen interactions, although at least one study has shown that syndecan-1 is 
dispensable for murine liver infection by Plasmodium yoelii (Bhanot & Nussenzweig, 2002). 
Theoretically, as being also expressed by hepatocytes, syndecan-4 might overtake some of 
the roles of syndecan-1, although it is present in minor amounts only and in a distinct, bile 
canalicular localization (Roskams et al., 1995). 
Syndecan-2, also called fibroglycan, is a mesenchymal-type syndecan. As such, it is produced 
by mesenchymal cells of the portal tract, but not by quiescent HSCs (Roskams et al., 1995). 
Syndecan-3, despite its general reputation as a neuronal syndecan, was also detected 
immunohistochemically in the normal liver, where it was localized to the endothelial lining of 
portal blood vessels, as well as to HSCs in the sinusoids (Roskams et al., 1995). 
The quantity and distribution of syndecans is affected in several ways by chronic liver 
disease. Regenerative hepatocytes in chronic cholestatic disease show increased syndecan-1 
expression which, accompanied by a relative gain in lateral membrane localization, results 
in an almost honeycomb-like immunostaining pattern (Roskams et al., 1996). Similar 
alterations occur in cirrhosis (Tátrai et al., 2010). Additionally, reactive ductules also exhibit 
strong syndecan-1 immunoreaction. Syndecan-3 is intensely seen in activated HSCs and 
macrophages. Disturbed polarity of hepatocytes is indicated not only by a less restricted 
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localization of syndecan-1, but also by the dispersion of granular syndecan-4 immunostaining 
originally concentrated around the bile canalicular pole (Roskams et al., 1996). 
In most HCCs, the honeycomb pattern of syndecan-1 immunostaining is preserved, and the 
overall intensity is increased relative to the normal liver (Roskams et al., 1998). However, 
syndecan-1 may be gradually silenced in parallel with tumor progression, and reduced 
expression of syndecan-1 has been shown to correlate with high metastatic potential 
(Matsumoto et al., 1997). Downregulation of syndecan-1 during the progression of epithelial 
cancers is a common phenomenon which, especially when accompanied by simultaneous 
loss of E-cadherin, is thought to indicate epithelial-to-mesenchymal transition (Iozzo & 
Sanderson, 2011). Loss of tumor cell syndecan-1 expression in carcinomas, occasionally 
combined with aberrant stromal expression of the same protein, is typically considered as a 
predictor of poor prognosis (for references, see Máthé et al., 2006). Stromal syndecan-1 in 
HCC has not been reported, but abnormal cytoplasmic, or even nuclear, staining in tumor 
cells was observed. Unlike syndecan-1, syndecan-2 in HCC appears on stromal 
mesenchymal cells, and syndecan-3 in vessel walls and on endothelial cells. Syndecan-4 is 
strikingly enhanced in HCC, with some tumor cells showing intense and diffuse 
cytoplasmic immunostaining. 
The functions of syndecans in chronic liver disease and HCC are largely unknown. 
Upregulation and increased shedding of syndecan-1 is characteristic of wound healing 
(Manon-Jensen et al., 2010), and fibrosis is a process analogous to wound healing in many 
aspects. Indeed, the amount of syndecan-1 ectodomains shed into the serum has been 
reported to reflect the severity of fibrosis (Zvibel at al., 2009). Additionally, it can be 
speculated that enhanced and broadened expression of syndecan-1 on the surface of 
hepatocytes may facilitate entry of hepatitis viruses, and thus create a positive feedback loop 
that may contribute to the perpetuation of infection in the fibrotic/cirrhotic liver (András 
Kiss, personal communication). 
The role of syndecan-1 in tumorigenesis and tumor progression is contradictory, and varies 
with tumor stage and type: it is downregulated in some carcinomas (e.g., certain breast 
cancers) but overexpressed by other tumors (e.g., pancreatic cancers, myelomas) (Manon-
Jensen et al., 2010). Based on an in vitro study performed with multiple HCC cell lines, it has 
been proposed that syndecan-1 and -4 may assist in the binding of the chemokine 
CCL5/RANTES, and thus promote migration and invasion of tumor cells (Charni et al., 2009). 
Glypicans. The glypican family (reviewed by Filmus et al., 2008) consists of six glycosyl-
phosphatidylinositol-anchored HSPGs with relatively small (555-580 amino acid) core 
proteins, and HS chains located close to the cell surface. Glypicans may also shed from the cell 
surface (and hence appear in the serum), and may undergo proteolytic cleavage. The main 
function of glypicans lies in regulating the signaling of Wnts, Hedgehogs (Hh’s), FGFs, and 
bone morphogenetic proteins (BMPs). Research has mostly been focused on glypican-3, luckily 
for us, since this is the only member of the family with true relevance to the liver. Glypican-3 
exerts opposite effects on Wnt and Hh pathways: it facilitates binding of Wnts to frizzled and 
increases signaling, whereas it competes with patched for Hh binding, and directs Hh toward 
endocytic breakdown, leaving smoothened and its signal cascade inactive (Filmus et al., 2008). 
In the liver, glypican-3 behaves as an oncofetal antigen: it is expressed in the fetal but not 
in the adult liver, and becomes re-expressed in hepatocytes upon malignant 
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transformation only. Quite intriguingly, although glypican-3 appears to be a negative 
regulator of growth during development and regeneration of the liver (Liu et al., 2009, 
2010), and its forced expression suppresses hepatocyte proliferation in mice (Lin et al., 
2011), glypican-3 is nearly uniformly overexpressed in human liver cancers, and glypican-
3-positive HCCs have significantly worse prognosis when compared to the relatively few 
glypican-3-negative cases (Shirakawa et al., 2009). In fact, glypican-3 has recently emerged 
as one of the most promising immunocytochemical, immunohistochemical and serum 
markers of HCC. Glypican-3, in combination with other markers, has been shown to 
facilitate detection of early HCC both in biopsies and from the serum (Roskams & Kojiro, 
2010; Malaguarnera et al., 2010). 
Glypican-3 is thought to promote HCC progression through multiple mechanisms. 
Overexpression of glypican-3 in HCC was not only found to correlate with enhanced 
nuclear localization of ┚-catenin (indicating its role as a stimulator of Wnt signaling), but 
also with increased expression of matrix metalloproteinases, members of the FGF signaling 
pathway, and SULF2 (Akutsu et al., 2010). Oncogenic potential of GPC-3 may be related to 
its ability to stimulate IGF-II / IGF-1R interaction, too (Cheng et al., 2008). Activation of all 
the above-mentioned molecules and pathways had been observed previously in HCC, and 
hypotheses can now be formulated as to whether and how they are mechanistically related 
to the upregulation of glypican-3. Yet it is difficult to foresee at the moment how the 
supposed anti-proliferative and pro-oncogenic effects of glypican-3 can be consolidated into 
a single self-consistent theory. Also, while some important details of the transcriptional 
regulation of glypican-3 have been elucidated (Morford et al., 2007), the basis for its re-
activation in HCC remains to be investigated. 
2.2.3 Enzymes involved in HS synthesis and modification 
As chronic liver diseases and HCC bring about profound alterations in HSPG synthesis, it is 
logical to expect accompanying changes in the levels and/or activities of enzymes involved 
in HS synthesis and modification. Moreover, it has been demonstrated that besides a rise in 
its quantity, the fine structure (and, consequently, the biological activity) of HS also becomes 
altered in HCC (Dudás et al., 2000). So far, however, very little attention has been directed 
toward the expression and activity of NDSTs and OSTs (the enzymes transferring sulfates 
on the nascent HS chain) in the healthy and diseased liver. The role of heparanase and 
SULFs in HCC progression has apparently attracted more interest. 
NDSTs and OSTs. NDSTs substitute the acetyl group with sulfate on glucosamine, while 
OSTs place sulfates on selected disaccharide units at the 6-O- and 3-O-positions of 
glucosamine, as well as at the 2-O-position of the uronic acid. N-sulfation, uronic acid 
epimerization, and O-sulfation are not independent steps; rather, they follow a hierarchy 
suggested by the above order (Murphy et al., 2004). Both NDST isoforms NDST-1 and -2 
have been reported to be present and enzymatically active in the healthy liver, although 
NDST-2 does not seem to contribute to HS sulfation (Ledin et al., 2006). Out of the many 2-, 
3- and 6-OSTs, only a few isoforms have been detected in the normal liver (Shworak et al., 
1999). The relative neglect of these enzymes in research is probably unjust, as they make key 
contributions to the synthesis of functional liver HS. Specifically, N- and 2-O-sulfated (and 
probably also 6-O-sulfated) HS is necessary for remnant lipoprotein uptake (Stanford et al., 
2010; K. Chen et al., 2010), and various highly sulfated HS motifs are required for the 
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interaction of parenchymal cells with pathogens such as Plasmodium sporozoites or hepatitis 
B and C viruses (Barth et al., 2006; Coppi et al., 2007; Schulze et al., 2007). Suppressed NDST 
expression in diabetes has been suggested to impair lipoprotein uptake and thus worsen 
dyslipidemia (Williams et al., 2005). 
Both NDST isoforms, as well as 3-OST-1 and 6-OST-1 have been found to be overexpressed 
in fibrotic liver diseases and HCC. The enzymes 2-OST-1 and 3-OST-3B, on the other hand, 
were highly expressed in the normal liver but not significantly upregulated in disease 
(Tátrai et al., 2010). Although the clinicopathologic significance of these alterations are 
unknown, it can be speculated that overexpression of 3-OST-1, the 3-OST isoform most 
potent in the synthesis of anticoagulant HS (Girardin et al., 2005), coupled with release of 
liver HS into the bloodstream by heparanase, may contribute to the coagulopathy observed 
in some cirrhotic patients. Altered HS structure created by hyperactive 3-OSTs may also 
influence signaling pathways involved in oncogenesis. 
Heparanase (reviewed by Levy-Adam et al., 2010) is an endo-┚-D-glucuronidase capable of 
cleaving HS chains in a limited fashion. Fragmentation of HS by heparanase (HPSE) breaks 
the integrity of the ECM and BMs, and mobilizes bound growth factors. Such remodeling of 
the ECM is generally thought to promote multiple steps of tumor progression including 
angiogenesis, invasion, and metastasis. Hence, it is not surprising that high expression of 
HPSE is an unfavorable prognostic factor in most tumor types (Barash et al, 2010). In fact, 
the mechanism of action of HPSE in tumors is much more complex and goes beyond growth 
factor mobilization. E.g., increased HPSE activity enhances syndecan-1 shedding, either 
directly or via induction of MMP-9; moreover, it influences clustering, PKC┙-mediated 
signaling, and internalization of syndecan-1 (Yang et al., 2007; Fux et al., 2009). HPSE also 
stimulates the production of hepatocyte growth factor (HGF) in an enzymatic activity-
independent fashion. Shed syndecan-1 may form active complexes with HGF, and further 
potentiate tumor growth (Ramani et al., 2011). Additional non-enzymatic effects of HPSE 
include enhanced Erk phosphorylation, as well as activation of the AKT and EGFR 
pathways (Fux et al., 2009). 
HPSE is detected in the developing liver, but not in the healthy adult organ. It becomes 
induced, however, during liver regeneration (Goldshmidt et al., 2004), and elevated HPSE 
mRNA levels were measured in fibrogenic liver diseases (Tátrai et al., 2010), although other 
studies have found no difference in the amount of HPSE protein between normal liver tissue 
and cirrhosis (Xiao et al., 2003; G. Chen et al., 2008). Despite its overall pro-oncogenic 
profile, literature data are equivocal on the role of HPSE in HCC progression (for a recent 
review, see Dong & Wu, 2010). The majority of papers report on the elevation of HPSE 
mRNA and/or protein in HCC relative to both adjacent non-tumorous and normal liver 
tissue, and most investigations have found significant positive correlation between tumoral 
HPSE levels, HCC progression, and adverse prognosis. In some studies, however, the levels 
of HPSE mRNA were found to be decreased in HCC when compared to adjacent non-
cancerous tissue (Ikeguchi et al., 2002, 2003), and mean HPSE mRNA expression was shown 
to be elevated in HCC relative to the healthy liver but lower than in fibrogenic diseases 
(Tátrai et al., 2010). In explanation of a supposed tumor-inhibitory effect it has been 
proposed that, as opposed to the stimulatory effect of moderate HPSE activity, excessive HS 
fragmentation by HPSE may be detrimental to FGF-2 signaling and may therefore lead to 
increased apoptosis rates (Ikeguchi et al., 2003; Dong & Wu, 2010). 
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SULFs (reviewed by Bret et al., 2011) are secreted endosulfatases that remove specific 6-O-
sulfates from HS. Both SULF1 and SULF2 have broad tissue distribution in the healthy 
human organism (Morimoto-Tomita et al., 2002). Although they catalyze the same 
reaction and possess similar substrate specificities, the two enzymes appear to exert 
distinct effects. In mice, Sulf2 can complement the lack of Sulf1 during embryonic 
development, whereas Sulf2-knockout animals are born with severe central nervous 
system defects and die by day 14 postnatally (Kalus et al., 2009). Such differences in 
regulation and mechanism of action may explain the surprising observation that SULF1 
and SULF2 act oppositely in the process of tumorigenesis: unlike SULF1 that is generally 
regarded as a tumor suppressor, SULF2 is a pro-oncogenic endosulfatase overexpressed 
in several tumor types including HCC (Bret et al., 2011). 
In the healthy liver, SULF1 mRNA is expressed at low levels; SULF2 mRNA is approx. 10 
times more abundant. On the other hand, while average SULF2 mRNA levels are only 
slightly increased during chronic liver disease and HCC, SULF1 mRNA is robustly 
overexpressed in both conditions (Tátrai et al., 2010). Nevertheless, SULF1 has been proven 
to behave as a suppressor of HCC growth both in vitro and in vivo. By desulfating HS, it 
inhibits the co-receptor function of HSPGs in multiple heparin-binding growth factor – 
tyrosine kinase receptor pathways, and forced overexpression of SULF1 in HCC cell lines 
results in delayed xenograft growth (Lai et al., 2008a). While SULF1 is downregulated in 
30% of resected HCCs only, it was found to be silenced in 82% of established HCC cell lines 
(Lai et al., 2008b). This discrepancy between primary tumors and cell lines can possibly be 
explained by selection bias associated with in vitro culturing.  
SULF2, as a contrast, was found to be upregulated in 8/11 (72%) HCC cell lines and approx. 
60% of primary tumors, and patients with the highest SULF2 expression had significantly 
worse prognosis (Lai et al., 2008c). SULF2 enhances FGF-2 signaling, thereby promoting 
tumor cell growth and migration. Moreover, SULF2 upregulates both glypican-3 and Wnt3a 
expression of cancer cells, and facilitates release of Wnt3a from glypican-3 by desulfating its 
HS chains; the outcome is boosted Wnt/┚-catenin signaling (Lai et al., 2010). 
2.3 Other transmembrane PGs 
Membrane-spanning PGs other than syndecans include betaglycan, melanoma chondroitin 
sulfate proteoglycan (also known as CSPG4), neuropilin-1, and the variant forms of CD44 
(Couchman, 2010). Similar to syndecans, these transmembrane PGs may also interact with a 
plethora of extracellular partners; further, although their short intracytoplasmic domains 
lack intrinsic enzymatic activity, they may recruit cytoskeleton-associated and signaling 
molecules, often via their PDZ binding site. Since CSPG4, despite its discovery in several 
human tissues and cancer types after melanoma, has not been identified in the liver, it is 
omitted from our discussion. 
Betaglycan, also referred to as type III TGF┚ receptor, can be substituted with either HS or 
CS/DS (Couchman, 2010). As its alternate name indicates, betaglycan acts as a co-receptor 
for members of the TGF┚ family. Like neuropilin-1 (see below), betaglycan also has a close 
relative, endoglin, which shares sequence homology, some details of domain structure, and 
related functions with betaglycan, but lacks attached GAG (Bernabeu et al., 2009). 
Betaglycan seems to be implicated in epithelial-to-mesenchymal transition (EMT), and 
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betaglycan-null mouse embryos die in utero due to multiple malformations involving the 
heart and the liver (Stenvers et al., 2003). Paradoxically, while betaglycan is required to 
sustain TGF┚ signaling in embryonic cells undergoing EMT, it is silenced by most neoplastic 
cells embarking on the same process (Bernabeu et al., 2009). On the whole, betaglycan is 
considered as a suppressor of cancer progression that inhibits tumor cell migration, 
proliferation, invasion, and tumor angiogenesis; accordingly, it becomes downregulated in 
many human malignancies (Gatza et al., 2010). 
Although betaglycan expression of the healthy human liver tissue has not been 
investigated, it was shown to be expressed by cultured human and rat HSCs and 
myofibroblasts, and its mRNA levels decreased during transition from HSC to 
myofibroblast (Weiner et al., 1996; Meurer et al., 2005). In line with its accepted role as a 
tumor suppressor, expression of betaglycan mRNA was found to be reduced in 7/10 
HCCs relative to the corresponding normal liver tissues, and its levels were inversely 
correlated with tumor grade (Bae et al., 2009). 
CD44, a ubiquitous cell surface receptor of hyaluronan and other ECM components, is 
expressed in numerous variant forms (reviewed by Sackstein, 2011). Part of its diversity 
stems from a strikingly complex genomic structure: the human CD44 gene, besides 10 
‘standard’ exons, contains 9 functional ‘variant’ exons that can be alternatively spliced. 
Additionally, CD44 may undergo extensive posttranslational modifications, comprising the 
attachment of CS/DS, KS, and – in the presence of the v3 exon – also HS chains (van der 
Voort et al., 1999; Sackstein, 2011). The smallest form of CD44, termed CD44s, lacks all 
variant exons, and it is primarily expressed on cells of hematopoietic origin, including stem 
and progenitor cells, and mature but naïve lymphocytes. The larger, GAG-bearing variants 
(CD44v forms) appear on normal and cancerous epithelia, as well as on activated and 
malignantly transformed hematopoietic cells (Sackstein, 2011). A role for CD44 in tumor 
progression has long been suggested (Naor et al., 1997). More recently, standard and variant 
CD44 forms have been recognized as cancer stem cell markers (Keysar & Jimeno, 2010), and 
CD44 is among the genes that identify liver cancer stem cells (Liu et al., 2011). 
In the normal liver, only few hepatocytes were observed to exhibit weak membrane 
expression of CD44 (Endo & Terada, 2000). Elevated CD44 mRNA levels were measured in 
chronic liver diseases where the liver progenitor cell population is activated. High CD44 
mRNA expression was restricted to progenitor cells and reactive ductules, indicating that 
CD44 is a ‘stemness’ marker not only for cancer stem cells, but for non-malignant liver 
progenitors, too (Spee et al., 2010).  
Standard and variant forms of CD44 were upregulated in approx. half of HCCs investigated. 
High expression of CD44 on tumor cells was found to be associated with vascular invasion, 
and correlated with poorer disease outcome (Mathew et al., 1996; Endo & Terada, 2000). In 
an in vitro study, v3-containing, HS-decorated CD44 variants, but not the forms lacking the 
v3 exon, have been demonstrated to confer metastatic phenotype to an otherwise non-
metastatic HCC cell line, SKHep1 (Barbour et al., 2003). Therefore, high expression of CD44, 
and of CD44v3 in particular, might be positively correlated with a dominance of ‘stem-like’ 
character and aggressive behavior of HCC cells. 
Neuropilin-1 (NRP1) is a single-span transmembrane PG glycosylated with HS or CS/DS 
(Couchman, 2010). Just like its non-PG relative neuropilin-2, NRP1 has first been described 
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as a co-receptor for class 3 semaphorins, soluble signal molecules implicated in axonal 
guidance and vascular patterning (Adams & Eichmann, 2010). Later, neuropilins have also 
been identified as accessory receptors of VEGFs. NRP1 affects VEGFR signaling in a way 
that enhances migration and survival of endothelial cells, modulates vascular permeability, 
and stimulates angiogenesis (Koch et al., 2011). 
During development, NRP1 is broadly expressed in the vasculature, preferentially in 
arteries (Koch et al., 2011). In the adult liver, NRP1 immunostaining positively labels both 
sinusoidal and portal vessel endothelial cells, but not the hepatocytes (Bergé et al., 2011). 
When sinusoidal endothelium is subjected to increased shear stress, either in vitro or during 
liver regeneration following partial hepatectomy, NRP1 becomes upregulated in concert 
with other proangiogenic factors such as VEGF and angiopoetin-1 (Kraizer et al., 2001; Braet 
et al., 2004). NRP1 is also induced in HSCs upon activation, and has been shown to promote 
progression of fibrosis by stimulating platelet-derived growth factor- (PDGF-) dependent 
chemotaxis and TGF┚-mediated matrix deposition of myofibroblasts (Cao et al., 2010). 
In HCC, NRP1 expression is seen not only in endothelial cells of tumoral vessels, but – in 
approx. 50% of cases, and with variable intensity – in tumor hepatocytes, too. The 
significance of tumor cell NRP1 is unclear, but blocking NRP1-VEGF interaction was shown 
to inhibit vascular remodeling and growth of primary murine HCC (Bergé et al., 2011). 
2.4 Hyalectans 
Hyalectans are hyaluronan- and lectin-binding PGs of the ECM. They all share a tridomain 
structure, with the central domain carrying the majority of GAG chains (the number of 
which varies from 3 in brevican up to 100 in aggrecan), and the N- and C-terminal domains 
making contact with hyaluronan and lectins, respectively (Schaefer & Schaefer, 2010). 
Strategically positioned around hyaluronan, a principal ECM component, hyalectans 
regulate matrix assembly, and mediate a plethora of cell-ECM interactions. The group 
currently counts four members: versican, aggrecan, neurocan, and brevican. 
Although the CS/DSPG versican is expressed throughout the body, is known to regulate a 
multitude of cellular processes, and has been reported to contribute to the progression of 
several tumor types (Ricciardelli et al., 2009; Theocharis et al., 2010), no specific 
investigations have been targeted to versican in the liver, except for a single study where 
versican was detected in activated rat HSCs (Szende et al., 1992). With respect to the liver, 
even less is known about aggrecan, a CS/KSPG primarily found in cartilage and brain, and 
the CSPGs brevican and neurocan which have never been observed outside of the central 
nervous system (Theocharis et al., 2010). 
2.5 Secreted PGs: Endocan and PG-100 
Secreted PGs are ‘odd one outs’ in the new classification of PGs, being neither anchored to 
the cell surface nor immobilized in the ECM. Endocan (Béchard et al., 2001), or endothelial 
cell-specific molecule-1 (ESM-1), is a soluble PG by default which is secreted by endothelial 
cells directly into the bloodstream. Production of endocan by endothelial cells is boosted by 
both inflammatory and pro-angiogenic mediators; endocan, in turn, enhances HGF 
signaling. Endocan has been shown to be overexpressed in several human tumor types, and 
elevated serum levels in late-stage cancer patients is regarded as an adverse prognostic 
factor (Abid et al., 2006; Sarrazin et al., 2006). 
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 Proposed effect Therapeutic action Reference 
Level of 
evidence 
Decorin antifibrotic 
The protein inhibits matrix 
production of activated HSCs 
Shi et al.,
2006 
in vitro 
 antitumor 
The protein inhibits 
proliferation of HuH7 cells
Shangguan 
et al., 2009 
in vitro 
 antitumor 
Adenovirus-mediated gene 
transfer exhibits oncolytic 
activity on xenografted HCC 
Tralhão et 
al., 2003 
in vivo 
Collagen type 
XVIII / 
endostatin 
antitumor 
Adenovirus-mediated delivery 
of endostatin inhibits HCC 
xenograft growth 
Li et al., 2004 in vivo 
 antitumor 
Adeno-associated virus-
mediated delivery of endostatin 
reduces growth and 
vascularization of HCC 
xenograft 
Liu et al., 
2005 
in vivo 
 antitumor 
Forced expression of endostatin 
in xenografted HCC cells 
potentiates the action of 
doxorubicin 
Liu et al., 
2007 
in vivo 
Syndecan-1 
and -4 
antitumor 
Knockdown reduces 
CCL5/RANTES-dependent 
migration of HCC cells
Charni et al., 
2009 
in vitro 
Glypican-3 antitumor 
Humanized antibodies to GPC3 
evoke NK-mediated ADCC of 
HCC cells (phase I clinical trial 
recruiting) 
Ishiguro et 
al., 2008 
in vivo 
 antitumor 
A GPC3-derived peptide 
vaccine sensitizes CTLs against 
HCC cells
Yoshikawa 
et al., 2011 
phase I 
clinical 
trial 
SULF1 antitumor 
Forced expression inhibits HCC 
xenograft growth and 
potentiates the effect of HDAC 
inhibitors
Lai et al., 
2006 
in vivo 
Neuropilin-1 antifibrotic 
Knockout or silencing decreases 
motility of activated HSCs 
Cao et al.,
2010 
in vitro / 
in vivo 
 antitumor 
Blocking inhibits growth and 
vascular remodeling of primary 
murine HCC
Bergé et al., 
2011 
in vivo 
Endocan antitumor 
Silencing inhibits growth and 
migration of HCC cells
Kang et al., 
2011
in vitro 
Table 2. Proteoglycans in future therapies of chronic liver disease 
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Endocan is differentially expressed in the endothelium of HCC blood vessels, being absent 
from the sinusoids of both peritumoral non-malignant and healthy liver tissue; thus, 
immunohistochemistry for endocan helps visualize HCC vasculature (Huang et al., 2009). 
Endocan-positive microvessel density (MVD), unlike CD34-positive MVD, was shown to be 
predictive of poor survival, and high expression of endocan by tumoral endothelial cells 
correlated with the angiogenic and invasive potential of the tumor (Huang et al., 2009; L. Y. 
Chen et al., 2010). In a recent study, endocan production by tumoral hepatocytes has also 
been reported, and silencing of endocan has been shown to inhibit tumor cell growth and 
migration in vitro (Kang et al., 2011). 
PG-100 is the PG form of macrophage colony-stimulating factor and, as such, is a ‘part-time’ 
PG that may exist in a GAG-less or CS/DS-substituted form, the latter exhibiting less than 
1% of cytokine activity compared with the non-PG variant (Schwarz et al., 1990; 
Partenheimer et al. 1995). PG-100 was first discovered in the conditioned medium of 
osteosarcoma cells, and later found to be produced by other cell types including endothelia 
(Nelimarkka et al., 1997). PG-100 was only faintly immunostained in the normal liver, 
whereas in active fibrosis it was strongly visualized in bile duct epithelia, and thus proposed 
as a marker of ductular reaction (Högemann et al., 1997). The significance of this elevated 
expression remains to be clarified. 
3. Outlook: PGs in future therapies of chronic liver disease and HCC 
PGs are emerging therapeutic targets in inflammatory, fibrogenic and malignant diseases. 
As a summary to this review, in Table 2 we have collected some (however, by no means all) 
current attempts to exploit the multiple actions of PGs for countering the progression of 
chronic liver disease and HCC. Such experiments may involve delivery of PGs with 
supposed therapeutic effect, inhibition of those known to promote the pathologic process, 
modulation of HS structure, or application of HS-mimicking molecules. Some PGs 
expressed in the liver may be well-studied therapeutic targets in other organs or tumor 
types (e.g. perlecan, heparanase), yet have not been included in the list because their 
therapeutic potential has not been addressed specifically in the context of liver disease. The 
level of evidence (in vitro, in vivo) is also indicated in the table.  
Therapeutic approaches targeting glypican-3 have reached closest to human application; 
some phase I clinical trials have been completed or are underway. Several other PGs show 
remarkable promise, but these apparently have a longer way ahead. 
4. Acknowledgement 
Publication of this article was supported by the grants Nos. 67925 and 100904 from the 
Hungarian Scientific Research Fund (OTKA). 
5. References 
Abid, M. R., Yi, X., Yano, K., Shih, S. C. & Aird, W. C. (2006). Vascular endocan is 
preferentially expressed in tumor endothelium. Microvascular Research, Vol.72, 
No.3, (November 2006), pp. 136-145, ISSN 0026-2862 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
189 
Adams, R. H. & Eichmann, A. (2010). Axon guidance molecules in vascular patterning. Cold 
Spring Harbor Perspectives in Biology, Vol.2, No.5, (May 2010), a001875, ISSN 1943-
0264 
Akutsu, N., Yamamoto, H., Sasaki, S., Taniguchi, H., Arimura, Y., Imai, K. & Shinomura, Y. 
(2010). Association of glypican-3 expression with growth signaling molecules in 
hepatocellular carcinoma. World Journal of Gastroenterology, Vol.16, No.28, (July 
2010), pp. 3521-3528, ISSN 1007-9327 
Bae, H. J., Eun, J. W., Noh, J. H., Kim, J. K., Jung, K. H., Xie, H. J., Park, W. S., Lee, J. Y. & 
Nam, S. W. (2009). Down-regulation of transforming growth factor beta receptor 
type III in hepatocellular carcinoma is not directly associated with genetic 
alterations or loss of heterozygosity. Oncology Reports, Vol.22, No.3, (September 
2009), pp. 475-480, ISSN 1021-335X 
Baghy, K., Dezso, K., Laszlo, V., Fullar, A., Peterfia, B., Paku, S., Nagy, P., Schaff, Z., Iozzo, 
R. V. & Kovalszky, I. (2011). Ablation of the decorin gene enhances experimental 
hepatic fibrosis and impairs hepatic healing in mice. Laboratory Investigation, Vol.91, 
No.3, (March 2011), pp. 439-451, ISSN 1530-0307 
Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R. D., Ilan, N. & Vlodavsky, I. (2010). 
Proteoglycans in health and disease: new concepts for heparanase function in 
tumor progression and metastasis. FEBS Journal, Vol.277, No.19, (October 2010), pp. 
3890-3903, ISSN 1742-4658 
Barbour, A. P., Reeder, J. A., Walsh, M. D., Fawcett, J., Antalis, T. M. & Gotley, D. C. (2003). 
Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance 
of the heparan sulfate attachment site CD44v3. Cancer Research, Vol.63, No.4, 
(February 2003), pp. 887-892, ISSN 0008-5472 
Barth, H., Schafer, C., Adah, M. I., Zhang, F., Linhardt, R. J., Toyoda, H., Kinoshita-Toyoda, 
A., Toida, T., Van Kuppevelt, T. H., Depla, E, Von Weizsacker, F., Blum, H.E. & 
Baumert, T. F. (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 
requires cell surface heparan sulfate. The Journal of Biological Chemistry, Vol.278, 
No.42, (October 2003), pp. 41003-41012, ISSN 0021-9258 
Barth, H., Schnober, E. K., Zhang, F., Linhardt, R. J., Depla, E., Boson, B., Cosset, F. L., Patel, 
A. H., Blum, H. E. & Baumert, T. F. (2006). Viral and cellular determinants of the 
hepatitis C virus envelope-heparan sulfate interaction. Journal of Virology, Vol.80, 
No.21, (November 2006), pp. 10579-10590, ISSN 0022-538X 
Bechard, D., Gentina, T., Delehedde, M., Scherpereel, A., Lyon, M., Aumercier, M., Vazeux, 
R., Richet, C., Degand, P., Jude, B., Janin, A., Fernig, D. G., Tonnel, A. B. & Lassalle, 
P. (2001). Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan 
that promotes hepatocyte growth factor/scatter factor mitogenic activity. The 
Journal of Biological Chemistry, Vol.276, No.51, (December 2001), pp. 48341-48349, 
ISSN 0021-9258 
Berge, M., Allanic, D., Bonnin, P., de Montrion, C., Richard, J., Suc, M., Boivin, J. F., 
Contreres, J. O., Lockhart, B. P., Pocard, M., Levy, B. I., Tucker, G. C., Tobelem, G. 
& Merkulova-Rainon, T. (2011). Neuropilin-1 is upregulated in hepatocellular 
carcinoma and contributes to tumour growth and vascular remodelling. Journal of 
Hepatology, (February 2011), doi:10.1016/j.jhep.2011.01.033, ISSN 0168-8278 
Bernabeu, C., Lopez-Novoa, J. M. & Quintanilla, M. (2009). The emerging role of TGF-beta 
superfamily coreceptors in cancer. Biochimica et Biophysica Acta, Vol.1792, No.10, 
(October 2009), pp. 954-973, ISSN 0006-3002 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
190 
Bezakova, G. & Ruegg, M. A. (2003). New insights into the roles of agrin. Nature Reviews 
Molecular Cell Biology, Vol.4, No.4, (April 2003), pp. 295-308, ISSN 1471-0072 
Bhanot, P. & Nussenzweig, V. (2002). Plasmodium yoelii sporozoites infect Syndecan-1 
deficient mice. Molecular and Biochemical Parasitology, Vol.123, No.2, (August 2002), 
pp. 143-144, ISSN 0166-6851 
Bishop, J. R., Schuksz, M. & Esko, J. D. (2007). Heparan sulphate proteoglycans fine-tune 
mammalian physiology. Nature, Vol.446, No.7139, (April 2007), pp. 1030-1037, ISSN 
1476-4687 
Bix, G. & Iozzo, R. V. (2008). Novel interactions of perlecan: unraveling perlecan's role in 
angiogenesis. Microscopy Research and Technique, Vol.71, No.5, (May 2008), pp. 339-
348, ISSN 1059-910X 
Bradshaw, A. C., Parker, A. L., Duffy, M. R., Coughlan, L., van Rooijen, N., Kahari, V. M., 
Nicklin, S. A. & Baker, A. H. (2010). Requirements for receptor engagement during 
infection by adenovirus complexed with blood coagulation factor X. PLoS 
Pathogens, Vol.6, No.10, (2010), pii: e1001142. ISSN 1553-7374 
Braet, F., Shleper, M., Paizi, M., Brodsky, S., Kopeiko, N., Resnick, N. & Spira, G. (2004). 
Liver sinusoidal endothelial cell modulation upon resection and shear stress in 
vitro. Comparative Hepatology, Vol.3, No.1, (September 2004), p. 7, ISSN 1476-5926 
Breitkopf, K., Haas, S., Wiercinska, E., Singer, M. V. & Dooley, S. (2005). Anti-TGF-beta 
strategies for the treatment of chronic liver disease. Alcoholism, Clinical and 
Experimental Research, Vol.29, No.11 Suppl, (November 2005), pp. 121S-131S, ISSN 
0145-6008 
Bret, C., Moreaux, J., Schved, J. F., Hose, D. & Klein, B. (2011). SULFs in human neoplasia: 
implication as progression and prognosis factors. Journal of Translational Medicine, 
Vol.9, (2011), p. 72, ISSN 1479-5876 
Burgess, R. W., Dickman, D. K., Nunez, L., Glass, D. J. & Sanes, J. R. (2002). Mapping sites 
responsible for interactions of agrin with neurons. Journal of Neurochemistry, Vol.83, 
No.2, (October 2002), pp. 271-284, ISSN 0022-3042 
Cabello-Verrugio, C. & Brandan, E. (2007). A novel modulatory mechanism of transforming 
growth factor-beta signaling through decorin and LRP-1. The Journal of Biological 
Chemistry, Vol.282, No.26, (June 2007), pp. 18842-18850, ISSN 0021-9258 
Cao, S., Yaqoob, U., Das, A., Shergill, U., Jagavelu, K., Huebert, R. C., Routray, C., 
Abdelmoneim, S., Vasdev, M., Leof, E., Charlton, M., Watts, R. J., Mukhopadhyay, 
D. & Shah, V. H. (2010). Neuropilin-1 promotes cirrhosis of the rodent and human 
liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. Journal of 
Clinical Investigation, Vol.120, No.7, (July 2010), pp. 2379-2394, ISSN 1558-8238 
Charni, F., Friand, V., Haddad, O., Hlawaty, H., Martin, L., Vassy, R., Oudar, O., Gattegno, 
L., Charnaux, N. & Sutton, A. (2009). Syndecan-1 and syndecan-4 are involved in 
RANTES/CCL5-induced migration and invasion of human hepatoma cells. 
Biochimica et Biophysica Acta, Vol.1790, No.10, (October 2009), pp. 1314-1326, ISSN 
0006-3002 
Chen, G., Dang, Y. W., Luo, D. Z., Feng, Z. B. & Tang, X. L. (2008). Expression of heparanase 
in hepatocellular carcinoma has prognostic significance: a tissue microarray study. 
Oncology Research, Vol.17, No.4, (2008), pp. 183-189, ISSN 0965-0407 
Chen, J. & Liu, J. (2005). Characterization of the structure of antithrombin-binding heparan 
sulfate generated by heparan sulfate 3-O-sulfotransferase 5. Biochimica et Biophysica 
Acta, Vol.1725, No.2, (September 2005), pp. 190-200, ISSN 0006-3002 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
191 
Chen, K., Liu, M. L., Schaffer, L., Li, M., Boden, G., Wu, X. & Williams, K. J. (2010). Type 2 
diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that 
suppresses uptake of remnant lipoproteins. Hepatology, Vol.52, No.6, (December 
2010), pp. 1957-1967, ISSN 1527-3350 
Chen, L. Y., Liu, X., Wang, S. L. & Qin, C. Y. (2010). Over-expression of the Endocan gene in 
endothelial cells from hepatocellular carcinoma is associated with angiogenesis and 
tumour invasion. The Journal of International Medical Research, Vol.38, No.2, (March-
April 2010), pp. 498-510, ISSN 0300-0605 
Chen, Y., Gotte, M., Liu, J. & Park, P. W. (2008). Microbial subversion of heparan sulfate 
proteoglycans. Molecules and Cells, Vol.26, No.5, (November 2008), pp. 415-426, 
ISSN 1016-8478 
Cheng, W., Tseng, C. J., Lin, T. T., Cheng, I., Pan, H. W., Hsu, H. C. & Lee, Y. M. (2008). 
Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling 
pathway. Carcinogenesis, Vol.29, No.7, (July 2008), pp. 1319-1326, ISSN 1460-2180 
Chung, E. J., Sung, Y. K., Farooq, M., Kim, Y., Im, S., Tak, W. Y., Hwang, Y. J., Kim, Y. I., 
Han, H. S., Kim, J. C. & Kim, M. K. (2002). Gene expression profile analysis in 
human hepatocellular carcinoma by cDNA microarray. Molecules and Cells, Vol.14, 
No.3, (December 2002), pp. 382-387, ISSN 1016-8478 
Coppi, A., Tewari, R., Bishop, J. R., Bennett, B. L., Lawrence, R., Esko, J. D., Billker, O. & 
Sinnis, P. (2007). Heparan sulfate proteoglycans provide a signal to Plasmodium 
sporozoites to stop migrating and productively invade host cells. Cell Host & 
Microbe, Vol.2, No.5, (November 2007), pp. 316-327, ISSN 1934-6069 
Corjon, S., Gonzalez, G., Henning, P., Grichine, A., Lindholm, L., Boulanger, P., Fender, P. & 
Hong, S. S. (2011). Cell entry and trafficking of human adenovirus bound to blood 
factor X is determined by the fiber serotype and not hexon:heparan sulfate 
interaction. PLoS One, Vol.6, No.5, (2011), e18205, ISSN 1932-6203 
Couchman, J. R. (2010). Transmembrane signaling proteoglycans. Annual Review of Cell and 
Developmental Biology, Vol.26, (November 2010), pp. 89-114, ISSN 1530-8995 
Di Paolo, N. C., Kalyuzhniy, O. & Shayakhmetov, D. M. (2007). Fiber shaft-chimeric 
adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. 
Journal of Virology, Vol.81, No.22, (November 2007), pp. 12249-12259, ISSN 0022-
538X 
Dong, S. & Wu, X. Z. (2010). Heparanase and hepatocellular carcinoma: promoter or 
inhibitor? World Journal of Gastroenterology, Vol.16, No.3, (January 2010), pp. 306-
311, ISSN 1007-9327 
Dreyfuss, J. L., Regatieri, C. V., Jarrouge, T. R., Cavalheiro, R. P., Sampaio, L. O. & Nader, H. 
B. (2009). Heparan sulfate proteoglycans: structure, protein interactions and cell 
signaling. Anais da Academia Brasileira de Ciências, Vol.81, No.3, (September 2009), 
pp. 409-429, ISSN 1678-2690 
Dudas, J., Kovalszky, I., Gallai, M., Nagy, J. O., Schaff, Z., Knittel, T., Mehde, M., Neubauer, 
K., Szalay, F. & Ramadori, G. (2001). Expression of decorin, transforming growth 
factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in 
chronic hepatitis. American Journal of Clinical Pathology, Vol.115, No.5, (May 2001), 
pp. 725-735, ISSN 0002-9173 
Dudas, J., Ramadori, G., Knittel, T., Neubauer, K., Raddatz, D., Egedy, K. & Kovalszky, I. 
(2000). Effect of heparin and liver heparan sulphate on interaction of HepG2-
derived transcription factors and their cis-acting elements: altered potential of 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
192 
hepatocellular carcinoma heparan sulphate. The Biochemical Journal, Vol.350 Pt 1, 
(August 2000), pp. 245-251, ISSN 0264-6021 
Endo, K. & Terada, T. (2000). Protein expression of CD44 (standard and variant isoforms) in 
hepatocellular carcinoma: relationships with tumor grade, clinicopathologic 
parameters, p53 expression, and patient survival. Journal of Hepatology, Vol.32, 
No.1, (January 2000), pp. 78-84, ISSN 0168-8278 
Esko, J. D., Kimata, K. & Lindahl, U. (2009). Proteoglycans and Sulfated 
Glycosaminoglycans. In: Essentials of Glycobiology. 2nd edition, Varki, A., Cummings, 
R. D., Esko, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., Etzler, M. E. 
(Ed.), Chapter 16, Cold Spring Harbor Laboratory Press, ISBN 978-0879697709, 
Cold Spring Harbor (NY), USA 
Fan, H., Zhao, Z., Quan, Y., Xu, J., Zhang, J. & Xie, W. (2007). DNA methyltransferase 1 
knockdown induces silenced CDH1 gene reexpression by demethylation of 
methylated CpG in hepatocellular carcinoma cell line SMMC-7721. European Journal 
of Gastroenterology and Hepatology, Vol.19, No.11, (November 2007), pp. 952-961, 
ISSN 0954-691X 
Filmus, J., Capurro, M. & Rast, J. (2008). Glypicans. Genome Biology, Vol.9, No.5, (2008), p. 
224, ISSN 1465-6914 
Folkman, J. (2006). Antiangiogenesis in cancer therapy--endostatin and its mechanisms of 
action. Experimental Cell Research, Vol.312, No.5, (March 2006), pp. 594-607, ISSN 
0014-4827 
Fux, L., Ilan, N., Sanderson, R. D. & Vlodavsky, I. (2009). Heparanase: busy at the cell 
surface. Trends in Biochemical Sciences, Vol.34, No.10, (October 2009), pp. 511-519, 
ISSN 0968-0004 
Gatza, C. E., Oh, S. Y. & Blobe, G. C. (2010). Roles for the type III TGF-beta receptor in 
human cancer. Cellular Signaling, Vol.22, No.8, (August 2010), pp. 1163-1174, ISSN 
1873-3913 
Gesemann, M., Brancaccio, A., Schumacher, B. & Ruegg, M. A. (1998). Agrin is a high-
affinity binding protein of dystroglycan in non-muscle tissue. The Journal of 
Biological Chemistry, Vol.273, No.1, (January 1998), pp. 600-605, ISSN 0021-9258 
Girardin, E. P., Hajmohammadi, S., Birmele, B., Helisch, A., Shworak, N. W. & de Agostini, 
A. I. (2005). Synthesis of anticoagulantly active heparan sulfate proteoglycans by 
glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a 
limiting precursor pool. The Journal of Biological Chemistry, Vol.280, No.45, 
(November 2005), pp. 38059-38070, ISSN 0021-9258 
Goldoni, S. & Iozzo, R. V. (2008). Tumor microenvironment: Modulation by decorin and 
related molecules harboring leucine-rich tandem motifs. International Journal of 
Cancer, Vol.123, No.11, (December 2008), pp. 2473-2479, ISSN 1097-0215 
Goldshmidt, O., Yeikilis, R., Mawasi, N., Paizi, M., Gan, N., Ilan, N., Pappo, O., Vlodavsky, 
I. & Spira, G. (2004). Heparanase expression during normal liver development and 
following partial hepatectomy. The Journal of Pathology, Vol.203, No.1, (May 2004), 
pp. 594-602, ISSN 0022-3417 
Gressner, A. M., Krull, N. & Bachem, M. G. (1994). Regulation of proteoglycan expression in 
fibrotic liver and cultured fat-storing cells. Pathology, Research and Practice, Vol.190, 
No.9-10, (October 1994), pp. 864-882, ISSN 0344-0338 
Henry, S.P., Takanosu, M., Boyd, T.C., Mayne, P.M., Eberspaecher, H., Zhou,W., de 
Crombrugghe, B., Hook, M. & Mayne, R. Expression pattern and gene 
characterization of asporin. A newly discovered member of the leucine-rich repeat 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
193 
protein family. The Journal of Biological Chemistry, Vol.276, No.15 (April 2001), pp. 
12212-12221, ISSN 1083-351X 
Hilgard, P. & Stockert, R. (2000). Heparan sulfate proteoglycans initiate dengue virus 
infection of hepatocytes. Hepatology, Vol.32, No.5, (November 2000), pp. 1069-1077, 
ISSN 0270-9139 
Hogemann, B., Edel, G., Schwarz, K., Krech, R. & Kresse, H. (1997). Expression of biglycan, 
decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathology, 
Research and Practice, Vol.193, No.11-12, (1997), pp. 747-751, ISSN 0344-0338 
Hu, T. H., Huang, C. C., Wu, C. L., Lin, P. R., Liu, S. Y., Lin, J. W., Chuang, J. H. & Tai, M. H. 
(2005). Increased endostatin/collagen XVIII expression correlates with elevated 
VEGF level and poor prognosis in hepatocellular carcinoma. Modern Pathology, 
Vol.18, No.5, (May 2005), pp. 663-672, ISSN 0893-3952 
Huang, G. W., Tao, Y. M. & Ding, X. (2009). Endocan expression correlated with poor 
survival in human hepatocellular carcinoma. Digestive Diseases and Sciences, Vol.54, 
No.2, (February 2009), pp. 389-394, ISSN 1573-2568 
Ikeguchi, M., Hirooka, Y. & Kaibara, N. (2003). Heparanase gene expression and its 
correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and 
carcinoma. European Journal of Cancer, Vol.39, No.1, (January 2003), pp. 86-90, ISSN 
0959-8049 
Ikeguchi, M., Ueta, T., Yamane, Y., Hirooka, Y. & Kaibara, N. (2002). Quantitative analysis of 
heparanase messenger RNA expression in hepatocellular carcinoma. Journal of 
Surgical Oncology, Vol.81, No.3, (November 2002), pp. 148-154; disscusion 154, ISSN 
0022-4790 
Iozzo, R. V. & Sanderson, R. D. (2011). Proteoglycans in cancer biology, tumour 
microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine, 
Vol.15, No.5, (May 2011), pp. 1013-1031, ISSN 1582-4934 
Iozzo, R. V. & Schaefer, L. (2010). Proteoglycans in health and disease: novel regulatory 
signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS 
Journal, Vol.277, No.19, (October 2010), pp. 3864-3875, ISSN 1742-4658 
Iozzo, R. V., Zoeller, J. J. & Nystrom, A. (2009). Basement membrane proteoglycans: 
modulators Par Excellence of cancer growth and angiogenesis. Molecules and Cells, 
Vol.27, No.5, (May 2009), pp. 503-513, ISSN 0219-1032 
Isaka, Y., Brees, D. K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N. A. & Border, W. A. (1996). 
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in 
rat kidney. Nature Medicine, Vol.2, No.4, (April 1996), pp. 418-423, ISSN 1078-8956 
Ishiguro, T., Sugimoto, M., Kinoshita, Y., Miyazaki, Y., Nakano, K., Tsunoda, H., Sugo, I., 
Ohizumi, I., Aburatani, H., Hamakubo, T., Kodama, T., Tsuchiya, M. & Yamada-
Okabe, H. (2008). Anti-glypican 3 antibody as a potential antitumor agent for 
human liver cancer. Cancer Research, Vol.68, No.23, (December 2008), pp. 9832-9838, 
ISSN 1538-7445 
Kalamajski, S. & Oldberg, A. (2010). The role of small leucine-rich proteoglycans in collagen 
fibrillogenesis. Matrix Biology, Vol.29, No.4, (May 2010), pp. 248-253, ISSN 1569-
1802 
Kalia, M., Chandra, V., Rahman, S. A., Sehgal, D. & Jameel, S. (2009). Heparan sulfate 
proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid 
protein and for viral infection. Journal of Virology, Vol.83, No.24, (December 2009), 
pp. 12714-12724, ISSN 1098-5514 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
194 
Kalus, I., Salmen, B., Viebahn, C., von Figura, K., Schmitz, D., D'Hooge, R. & Dierks, T. 
(2009). Differential involvement of the extracellular 6-O-endosulfatases Sulf1 and 
Sulf2 in brain development and neuronal and behavioural plasticity. Journal of 
Cellular and Molecular Medicine, Vol.13, No.11-12, (November-December 2009), pp. 
4505-4521, ISSN 1582-4934 
Kang, Y. H., Ji, N. Y., Lee, C. I., Lee, H. G., Kim, J. W., Yeom, Y. I., Kim, D. G., Yoon, S. K., 
Park, P. J. & Song, E. Y. (2011). ESM-1 silencing decreased cell survival, migration, 
and invasion and modulated cell cycle progression in hepatocellular carcinoma. 
Amino Acids, Vol.40, No.3, (March 2011), pp. 1003-1013, ISSN 1438-2199 
Keysar, S. B. & Jimeno, A. (2010). More than markers: biological significance of cancer stem 
cell-defining molecules. Molecular Cancer Therapeutics, Vol.9, No.9, (September 
2010), pp. 2450-2457, ISSN 1538-8514 
Koch, S., Tugues, S., Li, X., Gualandi, L. & Claesson-Welsh, L. (2011). Signal transduction by 
vascular endothelial growth factor receptors. The Biochemical Journal, Vol.437, No.2, 
(July 2011), pp. 169-183, ISSN 1470-8728 
Kovalszky, I., Nagy, P., Szende, B., Lapis, K., Szalay, F., Jeney, A. & Schaff, Z. (1998). 
Experimental and human liver fibrogenesis. Scandinavian Journal of Gastroenterology 
Supplement, Vol.228, (1998), pp. 51-55, ISSN 0085-5928 
Kraizer, Y., Mawasi, N., Seagal, J., Paizi, M., Assy, N. & Spira, G. (2001). Vascular 
endothelial growth factor and angiopoietin in liver regeneration. Biochemical and 
Biophysical Research Communications, Vol.287, No.1, (September 2001), pp. 209-215, 
ISSN 0006-291X 
Lai, J. P., Oseini, A. M., Moser, C. D., Yu, C., Elsawa, S. F., Hu, C., Nakamura, I., Han, T., 
Aderca, I., Isomoto, H., Garrity-Park, M. M., Shire, A. M., Li, J., Sanderson, S. O., 
Adjei, A. A., Fernandez-Zapico, M. E. & Roberts, L. R. (2010). The oncogenic effect 
of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-
dependent Wnt activation. Hepatology, Vol.52, No.5, (November 2010), pp. 1680-
1689, ISSN 1527-3350 
Lai, J. P., Sandhu, D. S., Shire, A. M. & Roberts, L. R. (2008a). The tumor suppressor function 
of human sulfatase 1 (SULF1) in carcinogenesis. Journal of Gastrointestinal Cancer, 
Vol.39, No.1-4, (2008), pp. 149-158, ISSN 1941-6628 
Lai, J. P., Thompson, J. R., Sandhu, D. S. & Roberts, L. R. (2008b). Heparin-degrading 
sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. 
Future Oncology, Vol.4, No.6, (December 2008), pp. 803-814, ISSN 1744-8301 
Lai, J. P., Sandhu, D. S., Yu, C., Han, T., Moser, C. D., Jackson, K. K., Guerrero, R. B., Aderca, 
I., Isomoto, H., Garrity-Park, M. M., Zou, H., Shire, A. M., Nagorney, D. M., 
Sanderson, S. O., Adjei, A. A., Lee, J. S., Thorgeirsson, S. S. & Roberts, L. R. (2008c). 
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, 
and decreases survival in hepatocellular carcinoma. Hepatology, Vol.47, No.4, (April 
2008), pp. 1211-1222, ISSN 1527-3350 
Lai, J. P., Yu, C., Moser, C. D., Aderca, I., Han, T., Garvey, T. D., Murphy, L. M., Garrity-
Park, M. M., Shridhar, V., Adjei, A. A. & Roberts, L. R. (2006). SULF1 inhibits tumor 
growth and potentiates the effects of histone deacetylase inhibitors in 
hepatocellular carcinoma. Gastroenterology, Vol.130, No.7, (June 2006), pp. 2130-
2144, ISSN 0016-5085 
Ledin, J., Ringvall, M., Thuveson, M., Eriksson, I., Wilen, M., Kusche-Gullberg, M., Forsberg, 
E. & Kjellen, L. (2006). Enzymatically active N-deacetylase/N-sulfotransferase-2 is 
present in liver but does not contribute to heparan sulfate N-sulfation. The Journal of 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
195 
Biological Chemistry, Vol.281, No.47, (November 2006), pp. 35727-35734, ISSN 0021-
9258 
Levy-Adam, F., Ilan, N. & Vlodavsky, I. (2010). Tumorigenic and adhesive properties of 
heparanase. Seminars in Cancer Biology, Vol.20, No.3, (June 2010), pp. 153-160, ISSN 
1096-3650 
Li, L., Huang, J. L., Liu, Q. C., Wu, P. H., Liu, R. Y., Zeng, Y. X. & Huang, W. L. (2004). 
Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. 
World Journal of Gastroenterol, Vol.10, No.13, (July 2004), pp. 1867-1871, ISSN 1007-
9327 
Lin, C. W., Mars, W. M., Paranjpe, S., Donthamsetty, S., Bhave, V. S., Kang, L. I., Orr, A., 
Bowen, W. C., Bell, A. W. & Michalopoulos, G. K. (2011). Hepatocyte proliferation 
and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-
dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 
transgenic mice. Hepatology, Vol.54, No.2, (August 2011), pp. 620-630, ISSN 1527-
3350 
Liu, B., Bell, A. W., Paranjpe, S., Bowen, W. C., Khillan, J. S., Luo, J. H., Mars, W. M. & 
Michalopoulos, G. K. (2010). Suppression of liver regeneration and hepatocyte 
proliferation in hepatocyte-targeted glypican 3 transgenic mice. Hepatology, Vol.52, 
No.3, (September 2010), pp. 1060-1067, ISSN 1527-3350 
Liu, B., Paranjpe, S., Bowen, W. C., Bell, A. W., Luo, J. H., Yu, Y. P., Mars, W. M. & 
Michalopoulos, G. K. (2009). Investigation of the role of glypican 3 in liver 
regeneration and hepatocyte proliferation. American Journal of Pathology, Vol.175, 
No.2, (August 2009), pp. 717-724, ISSN 1525-2191 
Liu, F., Tan, G., Li, J., Dong, X., Krissansen, G. W. & Sun, X. (2007). Gene transfer of 
endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular 
carcinomas in mice. Cancer Science, Vol.98, No.9, (September 2007), pp. 1381-1387, 
ISSN 1347-9032 
Liu, H., Peng, C. H., Liu, Y. B., Wu, Y. L., Zhao, Z. M., Wang, Y. & Han, B. S. (2005). 
Inhibitory effect of adeno-associated virus-mediated gene transfer of human 
endostatin on hepatocellular carcinoma. World Journal of Gastroenterology, Vol.11, 
No.22, (June 2005), pp. 3331-3334, ISSN 1007-9327 
Liu, L. L., Fu, D., Ma, Y. & Shen, X. Z. (2011). The Power and the Promise of Liver Cancer 
Stem Cell Markers. Stem Cells and Development, (August 2011), ISSN 1557-8534 
Lorenzo, P., Aspberg, A., Onnerfjord, P., Bayliss, M.T., Neame, P.J. & Heinegard, D. (2001). 
Identification and characterization of asporin. A novel member of the leucine-rich 
repeat protein family closely related to decorin and biglycan. The Journal of 
Biological Chemistry, Vol.276, No.15 (April 2001), pp. 12201-12211, ISSN 1083-351X 
Ly, M., Laremore, T.N. & Linhardt, R.J. (2010). Proteoglycomics: recent progress and future 
challenges. OMICS: a Journal of Integrative Biology, Vol.14, No.4, (August 2010), pp. 
389-399, ISSN 1557-8100 
Malaguarnera, G., Giordano, M., Paladina, I., Berretta, M., Cappellani, A. & Malaguarnera, 
M. (2010). Serum markers of hepatocellular carcinoma. Digestive Diseases and 
Sciences, Vol.55, No.10, (October 2010), pp. 2744-2755, ISSN 1573-2568 
Manon-Jensen, T., Itoh, Y. & Couchman, J. R. (2010). Proteoglycans in health and disease: the 
multiple roles of syndecan shedding. FEBS Journal, Vol.277, No.19, (October 2010), 
pp. 3876-3889, ISSN 1742-4658 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
196 
Mathe, M., Suba, Z., Nemeth, Z., Tatrai, P., Fule, T., Borgulya, G., Barabas, J. & Kovalszky, I. 
(2006). Stromal syndecan-1 expression is an adverse prognostic factor in oral 
carcinomas. Oral Oncology, Vol.42, No.5, (May 2006), pp. 493-500, ISSN 1368-8375 
Mathew, J., Hines, J. E., Obafunwa, J. O., Burr, A. W., Toole, K. & Burt, A. D. (1996). CD44 is 
expressed in hepatocellular carcinomas showing vascular invasion. Journal of 
Pathology, Vol.179, No.1, (May 1996), pp. 74-79, ISSN 0022-3417 
Matsumoto, A., Ono, M., Fujimoto, Y., Gallo, R. L., Bernfield, M. & Kohgo, Y. (1997). 
Reduced expression of syndecan-1 in human hepatocellular carcinoma with high 
metastatic potential. International Journal of Cancer, Vol.74, No.5, (October 1997), pp. 
482-491, ISSN 0020-7136 
Meurer, S. K., Tihaa, L., Lahme, B., Gressner, A. M. & Weiskirchen, R. (2005). Identification 
of endoglin in rat hepatic stellate cells: new insights into transforming growth 
factor beta receptor signaling. The Journal of Biological Chemistry, Vol.280, No.4, 
(January 2005), pp. 3078-3087, ISSN 0021-9258 
Miyasaka, Y., Enomoto, N., Nagayama, K., Izumi, N., Marumo, F., Watanabe, M. & Sato, C. 
(2001). Analysis of differentially expressed genes in human hepatocellular 
carcinoma using suppression subtractive hybridization. British Journal of Cancer, 
Vol.85, No.2, (July 2001), pp. 228-234, ISSN 0007-0920 
Morford, L. A., Davis, C., Jin, L., Dobierzewska, A., Peterson, M. L. & Spear, B. T. (2007). The 
oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and 
homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. 
Hepatology, Vol.46, No.5, (November 2007), pp. 1541-1547, ISSN 1527-3350 
Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S. & Rosen, S. D. (2002). 
Cloning and characterization of two extracellular heparin-degrading 
endosulfatases in mice and humans. The Journal of Biological Chemistry, Vol.277, 
No.51, (December 2002), pp. 49175-49185, ISSN 0021-9258 
Murphy, K. J., Merry, C. L., Lyon, M., Thompson, J. E., Roberts, I. S. & Gallagher, J. T. (2004). 
A new model for the domain structure of heparan sulfate based on the novel 
specificity of K5 lyase. The Journal of Biological Chemistry, Vol.279, No.26, (June 
2004), pp. 27239-27245, ISSN 0021-9258 
Musso, O., Rehn, M., Saarela, J., Theret, N., Lietard, J., Hintikka, Lotrian, D., Campion, J. P., 
Pihlajaniemi, T. & Clement, B. (1998). Collagen XVIII is localized in sinusoids and 
basement membrane zones and expressed by hepatocytes and activated stellate 
cells in fibrotic human liver. Hepatology, Vol.28, No.1, (July 1998), pp. 98-107, ISSN 
0270-9139 
Musso, O., Theret, N., Heljasvaara, R., Rehn, M., Turlin, B., Campion, J. P., Pihlajaniemi, T. & 
Clement, B. (2001a). Tumor hepatocytes and basement membrane-Producing cells 
specifically express two different forms of the endostatin precursor, collagen XVIII, 
in human liver cancers. Hepatology, Vol.33, No.4, (April 2001), pp. 868-876, ISSN 
0270-9139 
Musso, O., Rehn, M., Theret, N., Turlin, B., Bioulac-Sage, P., Lotrian, D., Campion, J. P., 
Pihlajaniemi, T. & Clement, B. (2001b). Tumor progression is associated with a 
significant decrease in the expression of the endostatin precursor collagen XVIII in 
human hepatocellular carcinomas. Cancer Research, Vol.61, No.1, (January 2001), pp. 
45-49, ISSN 0008-5472 
Mythreye, K. & Blobe, G. C. (2009). Proteoglycan signaling co-receptors: roles in cell 
adhesion, migration and invasion. Cellular Signaling, Vol.21, No.11, (November 
2009), pp. 1548-1558, ISSN 1873-3913 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
197 
Naor, D., Sionov, R. V. & Ish-Shalom, D. (1997). CD44: structure, function, and association 
with the malignant process. Advances in Cancer Research, Vol.71, (1997), pp. 241-319, 
ISSN 0065-230X 
Nelimarkka, L., Kainulainen, V., Schonherr, E., Moisander, S., Jortikka, M., Lammi, M., 
Elenius, K., Jalkanen, M. & Jarvelainen, H. (1997). Expression of small extracellular 
chondroitin/dermatan sulfate proteoglycans is differentially regulated in human 
endothelial cells. The Journal of Biological Chemistry, Vol.272, No.19, (May 1997), pp. 
12730-12737, ISSN 0021-9258 
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. 
R., Olsen, B. R. & Folkman, J. (1997). Endostatin: an endogenous inhibitor of 
angiogenesis and tumor growth. Cell, Vol.88, No.2, (January 1997), pp. 277-285, 
ISSN 0092-8674 
Partenheimer, A., Schwarz, K., Wrocklage, C., Kolsch, E. & Kresse, H. (1995). Proteoglycan 
form of colony-stimulating factor-1 (proteoglycan-100). Stimulation of activity by 
glycosaminoglycan removal and proteolytic processing. Journal of Immunology, 
Vol.155, No.12, (December 1995), pp. 5557-5565, ISSN 0022-1767 
Pellegrini, L. (2001). Role of heparan sulfate in fibroblast growth factor signalling: a 
structural view. Current Opinion in Structural Biology, Vol.11, No.5, (October 2001), 
pp. 629-634, ISSN 0959-440X 
Pinzon-Ortiz, C., Friedman, J., Esko, J. & Sinnis, P. (2001). The binding of the 
circumsporozoite protein to cell surface heparan sulfate proteoglycans is required 
for plasmodium sporozoite attachment to target cells. The Journal of Biological 
Chemistry, Vol.276, No.29, (July 2001), pp. 26784-26791, ISSN 0021-9258 
Pradel, G., Garapaty, S. & Frevert, U. (2002). Proteoglycans mediate malaria sporozoite 
targeting to the liver. Molecular Microbiology, Vol.45, No.3, (August 2002), pp. 637-
651, ISSN 0950-382X 
Quelard, D., Lavergne, E., Hendaoui, I., Elamaa, H., Tiirola, U., Heljasvaara, R., 
Pihlajaniemi, T., Clement, B. & Musso, O. (2008). A cryptic frizzled module in cell 
surface collagen 18 inhibits Wnt/beta-catenin signaling. PLoS One, Vol.3, No.4, 
(2008), e1878, ISSN 1932-6203 
Ramani, V. C., Yang, Y., Ren, Y., Nan, L. & Sanderson, R. D. (2011). Heparanase plays a dual 
role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF 
expression and activity. The Journal of Biological Chemistry, Vol.286, No.8, (February 
2011), pp. 6490-6499, ISSN 1083-351X 
Ricciardelli, C., Sakko, A. J., Ween, M. P., Russell, D. L. & Horsfall, D. J. (2009). The 
biological role and regulation of versican levels in cancer. Cancer Metastasis Reviews, 
Vol.28, No.1-2, (June 2009), pp. 233-245, ISSN 1573-7233 
Roskams, T., De Vos, R., David, G., Van Damme, B. & Desmet, V. (1998). Heparan sulphate 
proteoglycan expression in human primary liver tumours. Journal of Pathology, 
Vol.185, No.3, (July 1998), pp. 290-297, ISSN 0022-3417 
Roskams, T. & Kojiro, M. (2010). Pathology of early hepatocellular carcinoma: conventional 
and molecular diagnosis. Seminars in Liver Disease, Vol.30, No.1, (February 2010), 
pp. 17-25, ISSN 1098-8971 
Roskams, T., Moshage, H., De Vos, R., Guido, D., Yap, P. & Desmet, V. (1995). Heparan 
sulfate proteoglycan expression in normal human liver. Hepatology, Vol.21, No.4, 
(April 1995), pp. 950-958, ISSN 0270-9139 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
198 
Roskams, T., Rosenbaum, J., De Vos, R., David, G. & Desmet, V. (1996). Heparan sulfate 
proteoglycan expression in chronic cholestatic human liver diseases. Hepatology, 
Vol.24, No.3, (September 1996), pp. 524-532, ISSN 0270-9139 
Sackstein, R. (2011). The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass 
pathway' and other emerging perspectives. Current Opinion in Hematology, Vol.18, 
No.4, (July 2011), pp. 239-248, ISSN 1531-7048 
Sarrazin, S., Adam, E., Lyon, M., Depontieu, F., Motte, V., Landolfi, C., Lortat-Jacob, H., 
Bechard, D., Lassalle, P. & Delehedde, M. (2006). Endocan or endothelial cell 
specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new 
target for cancer therapy. Biochimica et Biophysica Acta, Vol.1765, No.1, (January 
2006), pp. 25-37, ISSN 0006-3002 
Schaefer, L. & Iozzo, R.V. (2008). Biological functions of the small leucine-rich 
proteoglycans: from genetics to signal transduction. The Journal of Biological 
Chemistry, Vol.283, No.31 (August 2008), pp. 21305-21309, ISSN 1083-351X 
Schaefer, L. & Schaefer, R.M. (2010). Proteoglycans: from structural compounds to signaling 
molecules. Cell and Tissue Research, Vol.339, No.1 (January 2010), pp. 237-246, ISSN 
1432-0878 
Schulze, A., Gripon, P. & Urban, S. (2007). Hepatitis B virus infection initiates with a large 
surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology, 
Vol.46, No.6, (December 2007), pp. 1759-1768, ISSN 1527-3350 
Schwarz, K., Breuer, B. & Kresse, H. (1990). Biosynthesis and properties of a further member of 
the small chondroitin/dermatan sulfate proteoglycan family. The Journal of Biological 
Chemistry, Vol.265, No.35, (December 1990), pp. 22023-22028, ISSN 0021-9258 
Seppinen, L. & Pihlajaniemi, T. (2011). The multiple functions of collagen XVIII in 
development and disease. Matrix Biology, Vol.30, No.2, (March 2011), pp. 83-92, 
ISSN 1569-1802 
Shangguan, J. Y., Dou, K. F., Li, X., Hu, X. J., Zhang, F. Q., Yong, Z. S. & Ti, Z. Y. (2009). 
[Effects and mechanism of decorin on the proliferation of HuH7 hepatoma 
carcinoma cells in vitro]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, Vol.25, No.9, 
(September 2009), pp. 780-782, ISSN 1007-8738 
Shi, Y. F., Zhang, Q., Cheung, P. Y., Shi, L., Fong, C. C., Zhang, Y., Tzang, C. H., Chan, B. P., 
Fong, W. F., Chun, J., Kung, H. F. & Yang, M. (2006). Effects of rhDecorin on TGF-
beta1 induced human hepatic stellate cells LX-2 activation. Biochimica et Biophysica 
Acta, Vol.1760, No.11, (November 2006), pp. 1587-1595, ISSN 0006-3002 
Shirakawa, H., Suzuki, H., Shimomura, M., Kojima, M., Gotohda, N., Takahashi, S., Nakagohri, 
T., Konishi, M., Kobayashi, N., Kinoshita, T. & Nakatsura, T. (2009). Glypican-3 
expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer 
Science, Vol.100, No.8, (August 2009), pp. 1403-1407, ISSN 1349-7006 
Shworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. 
A. & Rosenberg, R. D. (1999). Multiple isoforms of heparan sulfate D-glucosaminyl 
3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas 
and identification of distinct genomic loci. The Journal of Biological Chemistry, 
Vol.274, No.8, (February 1999), pp. 5170-5184, ISSN 0021-9258 
Spee, B., Carpino, G., Schotanus, B. A., Katoonizadeh, A., Vander Borght, S., Gaudio, E. & 
Roskams, T. (2010). Characterisation of the liver progenitor cell niche in liver 
diseases: potential involvement of Wnt and Notch signalling. Gut, Vol.59, No.2, 
(February 2010), pp. 247-257, ISSN 1468-3288 
www.intechopen.com
 
Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update 
 
199 
Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L. & 
Esko, J. D. (2009). Syndecan-1 is the primary heparan sulfate proteoglycan 
mediating hepatic clearance of triglyceride-rich lipoproteins in mice. Journal of 
Clinical Investigation, Vol.119, No.11, (November 2009), pp. 3236-3245, ISSN 1558-
8238 
Stanford, K. I., Wang, L., Castagnola, J., Song, D., Bishop, J. R., Brown, J. R., Lawrence, R., 
Bai, X., Habuchi, H., Tanaka, M., Cardoso, W. V., Kimata, K. & Esko, J. D. (2010). 
Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein 
clearance. The Journal of Biological Chemistry, Vol.285, No.1, (January 2010), pp. 286-
294, ISSN 1083-351X 
Stenvers, K. L., Tursky, M. L., Harder, K. W., Kountouri, N., Amatayakul-Chantler, S., Grail, 
D., Small, C., Weinberg, R. A., Sizeland, A. M. & Zhu, H. J. (2003). Heart and liver 
defects and reduced transforming growth factor beta2 sensitivity in transforming 
growth factor beta type III receptor-deficient embryos. Molecular and Cellular 
Biology, Vol.23, No.12, (June 2003), pp. 4371-4385, ISSN 0270-7306 
Szende, B., Lapis, K., Kovalszky, I. & Timar, F. (1992). Role of the modified 
(glycosaminoglycan producing) perisinusoidal fibroblasts in the CCl4-induced 
fibrosis of the rat liver. In Vivo, Vol.6, No.4, (July-August 1992), pp. 355-361, ISSN 
0258-851X 
Tatrai, P., Dudas, J., Batmunkh, E., Mathe, M., Zalatnai, A., Schaff, Z., Ramadori, G. & 
Kovalszky, I. (2006). Agrin, a novel basement membrane component in human and 
rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Laboratory 
Investigation, Vol.86, No.11, (November 2006), pp. 1149-1160, ISSN 0023-6837 
Tatrai, P., Egedi, K., Somoracz, A., van Kuppevelt, T. H., Ten Dam, G., Lyon, M., Deakin, J. 
A., Kiss, A., Schaff, Z. & Kovalszky, I. (2010). Quantitative and qualitative 
alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. 
Journal of Histochemistry and Cytochemistry, Vol.58, No.5, (May 2010), pp. 429-441, 
ISSN 1551-5044 
Tatrai, P., Somoracz, A., Batmunkh, E., Schirmacher, P., Kiss, A., Schaff, Z., Nagy, P. & 
Kovalszky, I. (2009). Agrin and CD34 immunohistochemistry for the discrimination 
of benign versus malignant hepatocellular lesions. American Journal of Surgical 
Pathology, Vol.33, No.6, (June 2009), pp. 874-885, ISSN 1532-0979 
Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N. & Karamanos, N. K. (2010). 
Proteoglycans in health and disease: novel roles for proteoglycans in malignancy 
and their pharmacological targeting. FEBS Journal, Vol.277, No.19, (October 2010), 
pp. 3904-3923, ISSN 1742-4658 
Timar, J. & Kovalszky, I. (1995). Differential expression of proteoglycans on the surface of 
malignant cells and in the tumor stroma, In: Tumor Matrix Biology, Ádány, R. (Ed.), 
pp.23-53, CRC Press, ISBN 0-8493-4882-X, Boca Raton, Florida, USA. 
Tralhao, J. G., Schaefer, L., Micegova, M., Evaristo, C., Schonherr, E., Kayal, S., Veiga-
Fernandes, H., Danel, C., Iozzo, R. V., Kresse, H. & Lemarchand, P. (2003). In vivo 
selective and distant killing of cancer cells using adenovirus-mediated decorin gene 
transfer. FASEB Journal, Vol.17, No.3, (March 2003), pp. 464-466, ISSN 1530-6860 
van der Voort, R., Taher, T. E., Wielenga, V. J., Spaargaren, M., Prevo, R., Smit, L., David, G., 
Hartmann, G., Gherardi, E. & Pals, S. T. (1999). Heparan sulfate-modified CD44 
promotes hepatocyte growth factor/scatter factor-induced signal transduction 
through the receptor tyrosine kinase c-Met. The Journal of Biological Chemistry, 
Vol.274, No.10, (March 1999), pp. 6499-6506, ISSN 0021-9258 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
200 
Weiner, O. H., Zoremba, M. & Gressner, A. M. (1996). Gene expression of syndecans and 
betaglycan in isolated rat liver cells. Cell and Tissue Research, Vol.285, No.1, (July 
1996), pp. 11-16, ISSN 0302-766X 
Whitelock, J. M., Melrose, J. & Iozzo, R. V. (2008). Diverse cell signaling events modulated 
by perlecan. Biochemistry, Vol.47, No.43, (October 2008), pp. 11174-11183, ISSN 
1520-4995 
Williams, K. J. & Chen, K. (2010). Recent insights into factors affecting remnant lipoprotein 
uptake. Current Opinion in Lipidology, Vol.21, No.3, (June 2010), pp. 218-228, ISSN 
1473-6535 
Williams, K. J., Liu, M. L., Zhu, Y., Xu, X., Davidson, W. R., McCue, P. & Sharma, K. (2005). 
Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes, 
Vol.54, No.4, (April 2005), pp. 1116-1122, ISSN 0012-1797 
Xian, X., Gopal, S. & Couchman, J. R. (2010). Syndecans as receptors and organizers of the 
extracellular matrix. Cell and Tissue Research, Vol.339, No.1, (January 2010), pp. 31-
46, ISSN 1432-0878 
Xiao, Y., Kleeff, J., Shi, X., Buchler, M. W. & Friess, H. (2003). Heparanase expression in 
hepatocellular carcinoma and the cirrhotic liver. Hepatology Research, Vol.26, No.3, 
(July 2003), pp. 192-198, ISSN 1386-6346 
Yang, Y., Macleod, V., Miao, H. Q., Theus, A., Zhan, F., Shaughnessy, J. D., Jr., Sawyer, J., Li, 
J. P., Zcharia, E., Vlodavsky, I. & Sanderson, R. D. (2007). Heparanase enhances 
syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and 
metastasis. The Journal of Biological Chemistry, Vol.282, No.18, (May 2007), pp. 13326-
13333, ISSN 0021-9258 
Yoshikawa, T., Nakatsugawa, M., Suzuki, S., Shirakawa, H., Nobuoka, D., Sakemura, N., 
Motomura, Y., Tanaka, Y., Hayashi, S. & Nakatsura, T. (2011). HLA-A2-restricted 
glypican-3 peptide-specific CTL clones induced by peptide vaccine show high 
avidity and antigen-specific killing activity against tumor cells. Cancer Science, 
Vol.102, No.5, (May 2011), pp. 918-925, ISSN 1349-7006 
Yu, D. C., Chen, J., Sun, X. T., Zhuang, L. Y., Jiang, C. P. & Ding, Y. T. (2010). Mechanism of 
endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in 
hepatocellular carcinoma. BMC Cancer, Vol.10, (2010), p. 435, ISSN 1471-2407 
Zvibel, I., Halfon, P., Fishman, S., Penaranda, G., Leshno, M., Or, A. B., Halpern, Z. & Oren, 
R. (2009). Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver 
fibrosis stage in patients with hepatitis C. Liver International, Vol.29, No.2, (February 
2009), pp. 208-212, ISSN 1478-3231 
www.intechopen.com
Hepatocellular Carcinoma - Basic Research
Edited by Dr. Joseph W.Y. Lau
ISBN 978-953-51-0023-2
Hard cover, 402 pages
Publisher InTech
Published online 10, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hepatocellular Carcinoma represents a leading cause of cancer death and a major health problem in
developing countries where hepatitis B infection is prevalent. It has also become increasingly important with
the increase in hepatitis C infection in developed countries. Knowledge of hepatocellular carcinoma has
progressed rapidly. This book is a compendium of papers written by experts to present the most up-to-date
knowledge on hepatocellular carcinoma. This book deals mainly with the basic research aspect of
hepatocellular carcinoma. The book is divided into three sections: (I) Biomarkers / Therapeutic Target; (II)
Carcinogenesis / Invasion / Metastasis; and (III) Detection / Prevention / Prevalence. There are 18 chapters in
this book. This book is an important contribution to the basic research of hepatocellular carcinoma. The
intended readers of this book are scientists and clinicians who are interested in research on hepatocellular
carcinoma. Epidemiologists, pathologists, hospital administrators and drug manufacturers will also find this
book useful.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Péter Tátrai and Ilona Kovalszky (2012). Proteoglycans in Chronic Liver Disease and Hepatocellular
Carcinoma: An Update, Hepatocellular Carcinoma - Basic Research, Dr. Joseph W.Y. Lau (Ed.), ISBN: 978-
953-51-0023-2, InTech, Available from: http://www.intechopen.com/books/hepatocellular-carcinoma-basic-
research/proteoglycans-in-chronic-liver-disease-and-hepatocellular-carcinoma-an-update
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
